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Background: Chronic Obstructive Pulmonary Disease (COPD) patients have decreased 
physical activity (PA) levels compared to healthy controls. Their diurnal PA patterns are much 
less documented. Disturbed sleep is another common feature in COPD. The relationship between 
PA and sleep has never been reported in COPD patients. The project’s aims were to characterize 
objectively measured diurnal PA patterns and sleep quality, and explore the association between 
PA and sleep in COPD. 
Methods: Fourteen patients (aged 71±9 years) with mostly moderate COPD (FEV1: 
58±13% predicted) participated. PA and sleep parameters (Sleep Onset Latency[SOL], Wake 
After Sleep Onset[WASO], Total Sleep Time[TST], Sleep Efficiency[SE%], Fragmentation 
Index[FI]) were assessed via actigraphy for seven consecutive days, 24 hours/day. Diurnal PA 
patterns were evaluated by three handling approaches: arbitrary, mealtimes and equal tertiles. 
The interaction of period of the day by handling approach was tested with two-way repeated-
measured ANOVA. Associations between sleep parameters and mean daily PA and PA in each 
tertile was assessed with bivariate correlations.  
Results: There was a significant interaction effect of period of the day by handling 
approach (p<0.001). Regardless of the approach, PA significantly decreased in the evening 
compared to morning and afternoon. Participants had, on average: SOL: 22±17min, WASO: 
65±29min, TST: 383±59min, SE: 79±9% and FI: 45±23%. Mean daily PA and PA in each tertile 
showed very weak to moderate associations with sleep parameters (r = -0.50 to 0.42).  
Conclusion: PA levels drop in the evening in patients with moderate COPD. The 
relationship between PA and sleep quality appears modest in these patients, but the PA-sleep 
relationship warrants further investigation.  
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1.0 Theoretical Context  
Chronic Obstructive Pulmonary Disease (COPD) is a preventable and manageable lung 
disease characterized by a progressive airflow limitation; it represents one third of the most 
prevalent human health disorders in the world (1). The most recent Global initiative for 
Obstructive Lung Disease (GOLD) guidelines define COPD as “ a common preventable and 
manageable disease characterized by persistent airflow limitation that is usually progressive and 
associated with an enhanced chronic inflammatory response in the airways and the lungs to 
noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in 
individual patients.” (2). Furthermore, COPD has both pulmonary and extra-pulmonary 
components that include weight lost, nutritional abnormalities and skeletal muscle dysfunction 
(2-4).  
The term COPD has often been used as an umbrella term consisting of emphysema – 
which refers to the permanent enlargement of air spaces that are distal to the terminal bronchioles 
consequent to the destruction of alveolar walls (5) – and chronic bronchitis, which refers to the 
presence  of cough and sputum production for at least 3 months in a year for two consecutive 
years. However it is important to recognize that emphysema covers only one of the structural 
changes present in COPD, and that chronic bronchitis is an independent disease entity and also 
exists in patients with normal spirometry (2). The mechanisms underlying airflow limitation in 
COPD can be categorized into two groups: i) changes in the airway, such as increased airway 
resistance, airway inflammation, small airways disease and airway fibrosis or luminal plugs, and 
ii) changes at the alveolar level, such as parenchymal destruction, loss of alveolar attachments 
and decrease of elastic recoil (2) and, as a result of these the above changes, the ability to breathe 
normally is reduced (5). The symptoms of COPD include shortness of breath (dyspnea), 
coughing, wheezing, fatigue, frequent chest infections, and an overproduction of sputum (6). 
COPD is also frequently associated with lung cancer and is a major contributor to the 
development of cardiovascular disease as well as muscular atrophy and dysfunction (7). 
Progression of COPD typically follows a downward spiral called the “dyspnea spiral”, which 




deconditioning, which in turn worsen the dyspnea sensation in patients and eventually cause 
invalidity and poor quality of life. Figure-1 demonstrates this “dyspnea spiral”.  
    
 
  Figure 1 - COPD Downward Spiral  
  Adapted from la Clinique du soufflé la Solane, Osséja, France 
1.1 Burden of Chronic Obstructive Pulmonary Disease   
COPD is one of the leading causes of morbidity and mortality worldwide and therefore, it 
has substantial and increasing consequences on the social and economic status of the nation (2, 3, 
8). COPD is usually not diagnosed until it is clinically apparent and moderately advanced, and 
therefore tends to be greatly underestimated in its prevalence and morbidity data (8). As any 
other chronic disease, the prevalence, incidence, morbidity and mortality of COPD varies 
between countries and between different age groups within a country (2). 
COPD is the fifth leading cause of morbidity and the fourth leading cause of mortality (9) 
in developed countries and it is estimated that by 2030, it will be the third leading cause of death 
worldwide (10). However, due to the different definitions and terminologies used in the past, 
COPD has been under-recognized, under-diagnosed and under-treated (9). The increase in both 
mortality and morbidity of COPD is attributed to the continuous use of tobacco smoking and to 




Canada, although the disease is knowingly under-diagnosed, at least 700,000 adults (4.4% of 
adults 35 years and older) are reported as suffering from COPD according to a study published in 
2008 (11). However, a more recent study published in 2012 showed that 1.5 million people had 
been diagnosed with COPD in Canada, with a mortality rate of 10, 000 deaths per year (12).  
The incidence of COPD, which is the number of new cases in a certain amount of time, has 
also been reported in varying ranges across studies; it is therefore hard to summarize this 
information since it has been reported in different units and over different lengths of time. A 
longitudinal observational study reported a decreased in the incidence of COPD in Ontario, 
Canada, from 1996 to 2007 (13). The cumulative incidence rate decreased from 11.8 per 1000 
adults to 8.5 per 1000 adults. The decrease was greater in men (32.3%) compared to women 
(24.7%) and in older adults (≥ 65years) compared to young adults. 
COPD is associated with a significant economic burden, both directly and indirectly. 
Direct costs are those related to the detection, treatment, rehabilitation and prevention of the 
disease and mostly include hospital expenses, pharmacological and ambulatory care related to 
the COPD. Indirect costs are due to morbidity, missed work, premature mortality and disability. 
In Canada, the health cost for COPD was estimated at $4.52B in 2011 and is projected to reach 
$101.4B in societal costs over the next 25 years (12). COPD exacerbations account for the 
largest proportion of the COPD burden on the healthcare system and, as the disease progress, the 
expenses also increase with the greater cost being associated with more severe diagnoses of 
COPD (2).  
1.2 Risk Factors  
Recognition of risk factors for any disease is very important in the treatment and 
development of prevention measures. Generally, risk factors for a disease include host risk 
factors, which are endogenous, and environmental risk factors, which are exogenous (14). The 
current understanding of COPD risk factors are incomplete in many aspects, but it is believed 
that COPD results from interaction between environmental factors and different genotypes (2). 
The most important risk factor in developing COPD is undoubtedly tobacco smoking, as up to 




varies according to the country from 40-70% (15). Studies indicate that approximately 90% of 
patients suffering from COPD are smokers or individuals with a past history of smoking (16). 
However, not all smokers develop COPD, which points toward the interaction between smoking 
and other risk factors such as genetics, age and sex, exposure to particles, air pollution and 
respiratory infections that determines one’s susceptibility to COPD (9).  Figure-1 provides an 
overview of the possible risk factors for COPD. 
 
 
Figure 2 - Graphic Representation of the Risk Factors for COPD during Different Stages of Life.  
Upper left corner: Risk factors during in utero and perinatal life, Lower left corner: risk factors during early childhood, 
Lower right corner: risk factors during adulthood, Upper right corner: General risk factors are also shown  
         Adopted from Dirkje. S.P. The Lancet, 08, 2015 (17) 
 
1.3 Pathology, Pathogenesis and Pathophysiology of COPD  
Inflammation in the lungs is a normal response to noxious particles from inhaled cigarette 




(2). COPD is not a disease entity, but rather a complex of conditions that contribute to airflow 
limitation (18). These conditions include emphysema, which is destruction of parenchyma tissue 
and reduced surface for gas exchange, chronic bronchitis, which is a condition of large-airway 
inflammation and remodelling (19) and small airway fibrosis, which is disrupt normal repair and 
defense mechanisms (2). Progressive airflow limitation and air trapping is the result of the above 
pathological changes (2). The following section will address the underlying physiological 
changes that cause the progressive airflow limitation.   
1.3.1 Pathophysiology of COPD 
 The different pathogenic mechanisms that produce pathological changes in the respiratory track 
will cause physiological abnormalities (20), such as expiratory flow limitation and lung 
hyperinflation, gas exchange limitation, respiratory and peripheral muscle dysfunction, and 
exercise intolerance.   
1.3.1.1 Expiratory Flow Limitation and Lung Hyperinflation   
The term “expiratory flow limitation” indicates that maximum expiratory flow is reached 
during tidal breathing and indicates airflow obstruction in the intra-thoracic space (21).  The 
American Thoracic Society has a report on “Standards for the Diagnosis and Treatment of 
Patients with Chronic Obstructive Pulmonary Disease” which documents that the major sites of 
airflow limitation are small airways (i.e. airways smaller than 2 mm in diameter) and the 
limitation is mostly due to the remodelling of those airways (8). Other contributing factors for 
expiratory flow limitation are destruction of alveolar support and loss of elastic recoil, which is 
due to destruction of alveolar walls (22). On the other hand, expiratory airflow limitation 
promotes hyperinflation of the lungs, which is defined as “abnormal increase to the volume of air 
remaining in the lungs at the end of a spontaneous expiration” (23). Expiratory flow limitation 
not only causes lung hyperinflation, but also increases intrinsic positive end-expiratory pressure 
and work of breathing, and impairs function of inspiratory muscles (24). Lung hyperinflation in 
COPD patients is due to increased lung compliance, which in turn decreases inspiratory capacity 
resulting in an increase in functional residual capacity (7). As a result of these mechanisms, 
patients feel breathlessness (dyspneic) on exertion or even at rest in severe stages of the disease. 




Dynamic hyperinflation causes dyspnea and is considered one of the limiting factors for exercise 
capacity (8). Other contributing factors are accumulation of inflammatory cells, mucous and 
plasma exudate in the bronchi and smooth muscle contraction and dynamic hyperinflation during 
exercise (8). 
1.3.1.2 Respiratory and Peripheral Muscle Dysfunction  
By definition, muscle dysfunction is a loss or decrease in at least one of the main muscle 
functions: muscle strength and/or muscle endurance (25). Muscle endurance is defined as the 
ability to maintain sub-maximal effort over a prolonged period of time, where muscle strength is 
the ability to produce maximum contractile effort for a short period of time (26). Furthermore, 
muscle fatigue, which is loss of contractile function, can be chronic or acute (develop suddenly 
or gradually over long period of time), and partial or complete and it is resorted with rest (27). In 
COPD patients, all three components of muscle dysfunction, which are muscle weakness, muscle 
fatigue and reduced endurance are the result of complex interactions between several other 
factors that can be present at the same time. These factors and their biological consequences vary 
in respiratory and peripheral muscles, which are due to local and systematic factors (26). 
Respiratory muscles in COPD patients face increased mechanical ventilator loads due to 
airflow limitation, pulmonary hyperinflation and increased compliance (26).  The increased work 
of breathing and overload on respiratory muscles of COPD patients are due to the following 
three conditions: first, there is a decreased elastic recoil of the lung derived from changes in the 
thorax wall and lung parenchyma; second, there is an increased resistive load due to air passage 
through narrowed airways; and lastly, there is an increased threshold load derived from the 
intrinsic positive end-expiratory pressure (28, 29). On the other hand, static hyperinflation 
changes thorax geometry, causing the diaphragm to shorten (25). The condition can further get 
worse with dynamic hyperinflation upon exertion. This change in the optimum length of the 
diaphragm can affect its ability to generate force. The above changes lead to disturb mechanical 
demands of the respiratory system and functional capacity of the ventilatory muscles as well as the 
metabolic demands and energy supply to these muscles (26). Apart from the above local influences, 
systemic factors such as pulmonary gas exchange impairment, systematic inflammation, nutritional 
abnormalities, use of drugs for COPD treatment, tobacco use, and finally other comorbidities can 




About one-third of COPD patients experience peripheral muscle dysfunction, which could 
be due to many different factors such as systemic inflammation, systemic oxidative stress, gas 
exchange abnormalities, inefficiency of anabolic hormones, nutritional abnormalities, 
comorbidities, muscle wasting, tobacco, aging and the drugs used in treatment of COPD (26). In 
their review of the literature, Gea et al. (26) report that function impairment of peripheral 
muscles also has important clinical consequences for these patients and is associated with low 
exercise tolerance, reduced quality of life, greater use of health care resources, and increased 
mortality. It is shown that both muscle strength and endurance decrease in COPD patients. 
Particularly muscle strength decreases two to four times faster in COPD patients compared to 
healthy individuals (33, 34). It is important to note that there is a heterogeneity in limb muscle 
dysfunction in COPD; indeed, while some patients with mild to moderate airway obstruction 
exhibit muscle dysfunction, this muscle condition is absent in half of COPD patients with severe 
disease (35).  This variability for the same level of lung function suggests that other factors, such 
as muscle deconditioning potentially due to a sedentary lifestyle, play a role in muscle 
dysfunction in COPD patients.  
In summary, hyperinflation and increased preloads are the main factors for respiratory 
muscles dysfunction. Additionally, deconditioning due to inactivity is believed to be a main 
driver of muscle dysfunction in locomotor muscles of COPD patients (27). 
1.3.1.3 Exercise Intolerance  
One of the problematic symptom of COPD, which involves both central and peripheral 
factors, is exercise intolerance (36). It is shown that exercise intolerance is associated with 
functional impairment and disability. Additionally, it is a stronger predictor of poor quality of 
life and survival than either spirometry or oxygenation (37). In healthy untrained individuals, 
factors limiting exercise capacity are reaching maximum oxygen consumption (VO2max), 
dyspnea, and general or leg fatigue. However, in COPD patients, exercise capacity is limited by 
the interaction between multiple factors such as: impairment of ventilatory and respiratory 
mechanics, disease symptoms, gas exchange limitations and peripheral muscle (often leg) fatigue 
(36).  Throughout exercise, healthy subjects typically maintain their end-expiratory lung volume 




and depth of their breathing to adapt to the increased metabolic demand of their body. On the 
other hand, COPD patients have a reduced rate of lung emptying due to the decreased lung recoil 
and increased compliance (36). During exercise, end-expiratory lung volume therefore further 
increases as the time for lung emptying shortens, especially when patients experience 
hyperinflation at rest (36), leading to dynamic hyperinflation or additional air trapping during 
exercise (23).  This change in end-expiratory lung volume results in reduced inspiratory capacity, 
since total lung volume does not change (23). Further, COPD patients exhibit greater 
ventilation/perfusion abnormalities due to more pronounced ventilatory response for a given load 
compared to healthy individuals (23).  
Two main exercise limiting symptoms reported by COPD patients are leg fatigue and 
dyspnea (38). In their descriptive study, O’Donnell et al (39) reported that both COPD patients 
and healthy controls used terms like “increased work/effort” and “heaviness of breathing” to 
describe their shortness of breath or exertional dyspnea, but terms like “unsatisfied inspiratory 
effort” (i.e., “can’t get enough air in”), “inspiratory difficulty,” and “shallow breathing” were 
used by COPD patients alone, indicating the presence of hyperinflation in this patient population 
(39). Moreover, it was shown that the intensity of exertional dyspnea is associated with the level 
of dynamic hyperinflation reported by COPD patients. In general, patients with moderate to 
severe COPD have higher perception of dyspnea than leg fatigue during exercise (40), whereas 
in mild stages of the disease, the opposite is more often true (36). Exercise intolerance is also 
affected by training status and individual susceptibility to muscle fatigue (41), exercise 
modalities (42), and bronchodilation status (43).  
1.3.1.4 Comorbidities in COPD 
COPD is a disease of old age and it comes with other comorbid conditions. The most 
common comorbidities that are present in COPD patients are cardiovascular diseases, lung 
cancer, metabolic disorders, osteoporosis, anxiety and depression, skeletal muscle dysfunction, 
cachexia, gastrointestinal diseases, other respiratory conditions (44), sleep disorders (insomnia 
and obstructive sleep apnea), and anemia (45). It has been shown that a majority of COPD 
patients aged 45-year and over have at least one comorbid condition (46). Similarly, another 




condition and more than half (52%) had at least four coexisting conditions (47). Diagnosis and 
management of comorbidities of COPD patients are very important because evidence suggests a 
negative impact of comorbidities on patients’ outcome such as quality of life, exacerbation and 
mortality (45).    
1.4 Clinical Assessment of COPD 
COPD is a chronic progressive lung disease that is categorized into four stages based on 
spirometry results by GOLD (7). Table-1 presents the four stages of GOLD. 
Table 1 - Spirometry classification of COPD severity based on post-bronchodilator FEV1 
Classification of COPD severity to GOLD stages I-IV: Based on Post-bronchodilator 
FEV1 
In Patients with FEV1 /FVC < 0.7 
GOLD Stage I        Mild FEV1 ≥ 80% Predicted  
GOLD Stage II Moderate 50 % ≤ FEV1 ≤ 80% Predicted 
GOLD Stage III Severe  30 % ≤ FEV1 ≤ 50% Predicted 
GOLD Stage IV Very severe FEV1 ≤ 30% Predicted 
FEV1: forced expiratory volume in 1 sec, FVC: forced vital capacity, GOLD: Global Initiative for Chronic Obstructive Lung 
Disease 
Adapted from GOLD Report update, 2013 (2)  
1.4.1 Diagnosis of COPD 
COPD often has an initial undiagnosed phase during which the individual does not 
demonstrate any signs or symptoms of the disease. However, diagnosis should be considered if 
any of the signs or symptoms of the disease (such as chronic cough and/or production of sputum, 
and/or presence of dyspnea) and/or exposure to risk factors for the disease (such as smoking, air 
pollution, and/or history of COPD in the family) are present (20). Spirometry is the required test 







The four main symptoms of COPD are chronic and progressive dyspnea, cough, sputum 
production, and wheezing and chest tightness (7). Dyspnea is one of the major symptoms of 
COPD, which is described by COPD patients as  “unsatisfied inspiratory effort” (i.e., “can’t get 
enough air in”), “inspiratory difficulty,” and “shallow breathing.” (23). On the other hand, COPD 
patients can experience chronic cough, but disregard it as a consequence of smoking and/or 
environmental exposure (7). It is also called smoker’s cough and is often the first symptom of 
COPD (49). However, in some cases it might be absent even in the presence of significant 
airflow limitation (7). It can start with occasional coughing, but may become more persistent 
throughout the day (7). Sputum production, which is the production of a small quantity of 
persistent sputum after coughing bouts, is another symptom of COPD. It is also included in the 
definition of chronic bronchitis, which is regular production of sputum for more than 3 months in 
2 consecutive years; however, this is not the complete range of sputum production in COPD 
patients (2). Lastly, non-specific symptoms of COPD are wheezing and chest tightness and they 
vary between days and even within a day (2). Widespread wheezes can be present while listening 
to inspiration or expiration, where chest tightness may be present after exertion only, which 
could be due to isometric contraction of intercostal muscles (2).We should keep in mind that the 
presence of these symptoms does not confirm diagnosis of COPD and further physical 
examinations are necessary.  
1.4.1.2 Spirometry  
Spirometry, which is the most reproducible and objective measurement of airflow 
limitation (2), is a test that measures volume of air as a function of time as an individual inhales 
maximally and exhales forcefully and completely (50).  It is a physiological test that is 
considered the gold standard for the diagnosis of COPD. Spirometry consists of a forced vital 
capacity (FVC) manoeuvre, which has three distinct phases. It starts with maximum inspiration 
followed by a blast of exhalation and continues into complete exhalation (50). Before the test 
starts, the technician should make sure that the breathing tube is inserted into the subject’s mouth 
and the mouthpiece is well placed, so air does not skip (50). The test starts with full and rapid 
inspiration from the end of functional residual capacity, and then is followed by the FVC 




measures the time taken to empty the lungs. From this assessment, the subject’s FVC and forced 
expiratory volume in one second (FEV1) are measured. The ratio of FEV1/FVC should be 
obtained as well, and any person having a ratio of equal to or less than 0.7 is diagnosed with 
potential COPD (51). The test is done post-bronchodilator and the result is compared to the 
normal predicted value based on age, height, race and sex (2). The test has been used in many 
clinical trials due to its simplicity. Therefore, it has become the bases of most treatments and 
recommendations (2). Even though spirometry is the gold standard of the disease, it should be 
used in combination with other tests, such as chest X-ray and blood tests, to determine the 
severity of the disease in patients (20). 
1.4.1.3 Other Assessments   
COPD is a progressive disease and, once diagnosed, the severity of the disease should be 
assessed by evaluating symptoms of the disease as well as severity of the spirometry results, 
existence of other comorbidities, and the risk of exacerbations (2). Assessment of COPD 
symptoms can be done with several validated questionnaires such as the Modified British 
Medical Research Council (mMRC) and the COPD Assessment Test (CAT), which are 
recommended in the GOLD’s report 2013 report (2). However, the CAT is preferentially 
recommended, since it has broader coverage of the COPD impact on the patient’s daily quality of 
life and well-being, whereas the mMRC questionnaire measures disability due to dyspnea only 
(2). Further, exacerbation of COPD patients, which is an acute worsening of the patients 
respiratory symptoms such as breathlessness, coughing and sputum production beyond normal 
day-to-day variation that lasts for several days and is often treated with antibiotics (52), should 
be evaluated in the last 12 months (2). Frequency of exacerbation is shown to increase as the 
disease severity increases. As such, the exacerbation rate in a one-year follow-up of patients with 
moderate (Gold stage 2) COPD was 0.85, compared to 1.34 for severe patients (stage 3) and 2 
for very severe (stage 4) patients (53). Exercise testing, such as treadmill or cycle ergometer 
testing or the six-minute walk test, assess exertional dyspnea and muscular dysfunction and are 






1.5 Management of COPD 
At any stage of the disease, COPD is manageable (11) with adequate strategy. Proper 
management and treatment of COPD with both pharmacotherapy and non-pharmacological 
interventions can lead to improved symptoms and activity levels, and better quality of life.  
Management of COPD should address many aspects of the disease, starting with the prevention 
of disease progression, controlling respiratory symptoms (including dyspnea), reducing the 
frequency and severity of exacerbations (and associated treatments), improving exercise 
tolerance and quality of life and reducing mortality (11). Further, the management of COPD can 
be divided into prevention methods aimed at reducing risk factors – such as smoking cessation, 
decreasing occupational exposure to dust and air pollution, and increasing awareness of the 
disease – and intervention methods like pharmacotherapy, pulmonary rehabilitation, self-
management, oxygen therapy and surgery. Since the disease is progressive and impacts different 
aspects and levels of one’s life, a stepwise management that is comprehensive is recommended.  
Figure 1-illustrates the recommended treatments/interventions for COPD according to disease 
severity (54).    
 




1.6 Physical Activity in COPD  
Daily physical activity (DPA) has been shown to be a predictor of survival in the general 
population (55). Furthermore, it has been shown that in both men and women, physical inactivity 
increases with age, especially in individuals between 65-74 years of age and over 75. After the 
age of 74 in both sexes, regular physical activity (PA) is shown to decline considerably (56). 
Consequently, physical inactivity is already a concern in healthy older adults; in COPD patients, 
the scenario worsens (57). COPD is considered a disease of old age, mostly due to its 
manifestation after the age of 40. Additionally, an extensive literature review by Vorrink et al. 
(57) suggests that levels of DPA, including duration, intensity and counts of DPA, decrease 
significantly in COPD patients compared to healthy adults of similar age, sex and BMI. 
However, the extent to which physical inactivity affects the progression of COPD is not clear 
(57).  Katajisto et al (58) have shown that patient’s perception of dyspnea is positively associated 
with their level of physical inactivity and is disproportionally greater in relation to the decrease 
in lung function in inactive compared to active patients. In the last decades, measurements of 
daily PA have become an important outcome in COPD patients. 
1.6.1 Benefits of PA in COPD    
The advantage of exercise and PA on the physical and psychological well being of an 
individual is well documented (10). In COPD patients, PA is shown to be a predictor of all cause 
mortality (59). PA has been shown to have an inverse relation with hospital admission due to 
exacerbation (60) and all cause mortality rate in COPD patients (59, 61).  This is further 
confirmed in a recent study showing that low intensity PA negatively affects the risk of COPD 
hospitalization, however this was not shown with high-intensity PA (62). Yet, it was previously 
suggested that any level of moderate to vigorous PA significantly decreases 30-day hospital 
readmission in COPD patients (63). Garcia-Aymerich et al. (61) documented that COPD patients 
with higher PA levels seem to have better functional status, such as better diffusing capacity for 
carbon monoxide (DLCO), maximum oxygen uptake (VO2), maximal expiratory pressure (PEMAX) 
or in other terms, higher expiratory muscle strength, less systematic inflammation, and a better 
performance on the six-minute walk test (6MWT), which in itself is a predictor of all cause 




the Baecke questionnaire) can help in predicting frailty in both stable and exacerbated COPD 
(64). PA is also shown to reduce use of short-acting bronchodilators (60). Last but not least, it is 
important to recognize that PA is also shown to have significantly positive association with 
health-related quality of life (HRQL) in this patient population (65). 
Additionally, PA is also shown to have a protective effect on the risk of developing COPD 
by reducing the decline in lung function that is related to smoking (66).  PA reduces oxidative 
stress and the prevalence of upper respiratory infections, which could be due to its anti-
inflammatory response. This may explain the decrease in the detrimental consequences of 
smoking (67).  Several longitudinal studies on lung function have also documented an inverse 
relationship between decline in FEV1 and PA; they have shown a lower decline in lung function 
(FEV1) with increased PA (68, 69) and greater declines in lung function (FEV1) with lower PA 
levels (70, 71).  
1.6.2 Recommendations of PA for COPD  
Generally, PA recommendations address healthy populations, and PA recommendations 
for specific diseased population are either not clear (72) or not available. Available 
recommendations for healthy adults by the American College of Sports Medicine  (ACSM), the 
American Heart Association (AHA) (73) and the Canadian Society of Exercise Physiology 
(CSEP) (74) suggest 30 minutes of moderate PA for at least 5 days of the week, or 20 minutes of 
vigorous PA for at least 3 days of the week for older adults. Conversely, there are no specific 
guidelines for COPD patients, but there are a few suggestions for diseased populations in 
general. The World Health Organization (WHO) (75) recommends that adults with health 
problems who are not able to follow the above recommendations for PA should stay as active as 
their conditions allow them to. Further, ACSM (73) encourages elderly populations with chronic 
illness to adjust their PA level to their aerobic fitness and not use the absolute measures of 
intensity, since these measures do not take into account individual characteristics of patients such 
as disease severity and fitness levels. The recent recommendations published by ACSM (76) for 
prescribing individualized training programs based on objective measures such as oxygen uptake 
or heart rate for healthy individuals of all age groups can be prescribed to individuals with 




advantage of personalized recommendations is that, unlike absolute recommendations, they take 
into account individual’s aerobic fitness level and select the intensity of PA required to meet 
recommendations on the patient’s individual aerobic fitness level.  
As mentioned previously, there are no specific guidelines for DPA in COPD. To date, one 
study by Hartman et al. (72) has examined 7 different types of recommendations (three absolute 
and four relative and individualized) in COPD patients.  They documented that agreement 
between different PA recommendations were poor and the percentage of COPD patients meeting 
the recommendations ranged between 22 to 86%. Patients with light to moderate COPD (GOLD 
stage I and II) met the absolute recommendations better than the individualized 
recommendations, while patients with severe and very severe COPD (GOLD stage III and IV) 
met more the individualized recommendations based on their aerobic fitness levels. The former 
group (GOLD stage I and II) had significantly higher mean value for moderate intensity in the 
individualized recommendations compared to the absolute recommendations (p < 0.001), and in 
the later group (GOLD stage III and IV), the mean value for moderate intensity was lower in the 
individualized estimates compared to absolute measures of intensity (p < 0.001). However, when 
pooling all patient (GOLD stage I to IV) in one group, no significant difference was found 
between individualized and non-individualized recommendations. 
1.6.3 Measurements of Physical Activity in COPD 
To begin, it is important to differentiate between daily PA and exercise. Exercise is a 
planed, structured, and repetitive movement with the purpose of maintaining or improving one or 
more components of physical fitness [23].  On the other hand, PA is any body movement, which 
is produced by skeletal muscles and causes energy expenditure beyond the basal metabolic rate, 
or resting energy expenditure (77). DPA includes, but is not limited to, exercise. Additionally, it 
is suggested that DPA might not have substantial effects on health outcomes of active 
individuals, but in less active and sedentary individuals such as COPD, it might greatly impact 
their well-being (78).  
DPA can be assessed by direct observation, direct methods of free energy expenditure (EE) 




measurements (questionnaires or self-report) and objective measurements (motion sensors) [25]. 
The first two (direct observation and direct EE assessment) are rarely used due to impracticality, 
cost and availability, and because they demand highly skilled technicians (79). Therefore, other 
assessment methods such as subjective assessments (self-report, questionnaires, subject recall, 
and journals) and objective assessments (accelerometer and pedometers) are commonly used in 
most populations including COPD population (80).  
1.6.3.1 Subjective Measurements of DPA 
Subjective assessment of DPA includes questionnaires, self-reports, interviews and 
journals, and strongly relies on a person’s ability to recall details of DPA as well as on their 
personal judgment (over or under estimating their PA). To some degree, it can assess different 
aspects of PA, including duration, intensity and type of PA.  There are both advantages and 
disadvantages associated with subjective assessment of DPA.  
Subjectively quantifying DPA has the paramount advantage of being simple and 
inexpensive.  These methods are easy and can be self-applied, therefore, they often do not 
require skilled technicians, which further make them inexpensive to use. They can be applied 
from long distance, either by phone or mail, and even email. Therefore, participants do not have 
to come to a certain location in order to complete the questionnaire. An important point to keep 
in mind is that self-administered questionnaires should be short and easy to understand. Simple 
questionnaires have been shown to have high coefficients of validity and reliability (81). They 
are also more convenient for participants since they do not have to wear a motion sensor.  
However, the downside of subjective assessment is recall bias, which refers to the 
possibility that participants may not properly remember characteristics of the activity, such as 
intensity or duration, and mostly depends on the individual patient’s ability to recall and/or judge 
his/her level of PA.  As a general rule of thumb, shorter periods of recall are suggested to 
minimize recall bias, which may help participants to better judge their PA levels. Further, PA 
questionnaires do not differentiate individual characteristics of participants, such as body weight, 
which might influence the reliability of the estimated energy expenditure from activities (82). In 
addition, while using questionnaires, the length and complexity of the instrument should 




(especially if it is mailed), short questionnaires may limit the quantity of information received. 
Further, complex questionnaires may confuse the participant and decrease both the rate of return 
and the quality of response. The reliability and validity of questionnaires used should be tested 
against the gold standard, and if necessary should be modified for specific populations like 
COPD.  
There are many PA questionnaires, however, there is no recommendation on which 
questionnaire is most suitable to measure physical activity for elderly, and let alone one specific 
to COPD patients. For the elderly population, The Physical Activity Scale in the Elderly 
questionnaire has documented validity (83). Similarly, some physical activity questionnaires 
have been modified for COPD patients (79), such as the Lengthy Minnesota Leisure-Time 
Physical Activity Questionnaires, and Modified Baecke Physical Activity Questionnaire, with 
the later one having modest validity in COPD (79).  
1.6.3.2 Objective Measurements of DPA 
Pedometers and accelerometers are used to quantify PA during certain amounts of time 
(79). As their relative names suggest, pedometers, which are worn on the hip, provide step 
counts, while accelerometers, which are worn either on hip, arm, wrist, or ankle, sense body 
acceleration. Accelerometers can be uniaxial, biaxial or multi-axial, providing movement data on 
one direction, two directions or multiple directions, respectively.   
Pedometers are generally small instruments that are simple and relatively inexpensive (79).  
It has been shown that pedometers provide enough information to differentiate between different 
levels of PA in healthy adults (84). However, this is not documented in COPD patients (79). 
Furthermore, it has been shown that pedometers may underestimate the amount of PA, especially 
in sedentary populations with a slow walking pace (85). This could very well be the problem in 
COPD patients due to their slow walking pace, suggesting that pedometers may not be the 
appropriate device for the measurement of PA in frail populations (79). The pedometers 
suggested (especially during walking exercise) in COPD patients is Omron, since its reliability 




On the other hand, accelerometers are technologically more advanced than pedometers and 
can monitor and record data on quantity and intensity of movement (79). As mentioned 
previously, they can be uniaxial (monitoring data in one direction only) or multi-axial 
(monitoring data from multiple directions). The output of uniaxial accelerometers can be 
compared with pedometers since they are both in one direction, but accelerometers provide 
further information on the intensity of PA and PA in different periods of time (79). Multi-axial 
accelerometers are more advanced than uniaxial accelerometers in monitoring and storing data. 
Some devices also provide data on body position (lying down, sitting and standing) and different 
types of PA. However since they are more advanced, the cost to use these devices in clinical 
settings is also high and they also add to the need for technical expertise and specialized software 
(79). 
The major disadvantage associated with many types of accelerometers available is that 
their output varies between models (activity count, energy expenditure, PA level, vector 
magnitude unit, etc.) of different companies and therefore this makes it almost impossible to 
compare the final results between them. This variability in the output is due to the use of 
different algorithms by different models. Also, accelerometers can give false or in accurate 
readings in activities with static trunk, (79), or static wrist when the accelerometer is on the 
wrist,  or by recording noise such as car vibrations as body movements.  
To date, multiple accelerometers and pedometers have been used to monitor DPA in 
COPD patients. Bossenbroek et al (87), in their systematic review of Daily Physical Activity in 
Patients with Chronic Obstructive Disease, documented 17 studies using objective methods to 
monitor DPA. The most frequent accelerometer used was the DynaPort accelerometer (used in 8 
studies). Furthermore, validating six activity monitors against indirect calorimetry (VO2) showed 
that triaxial accelerometers provided more valid results compared to uniaxial accelerometers. 
Both minute-by-minute, and 59-minute average correlations between VO2 and output of activity 
monitors (Dynaport MiniMod, Actigraph, GT3X, SenseWear Armband and RT3) were high. For 
average 59-minute output, three triaxial monitors (SenseWear (r = 0.76), Actigraph (r = 0.49) 
and MiniMod (r = 0.45)) and one uniaxial monitor (KenZ Lifecorder (r=0.52) had the best 




speed (r = 0.94, r = 0.88, respectively) (88). It was shown that activity monitors were capable of 
detecting activity levels within the range of 1 to 1.5 METs in COPD patients.  
There have thus been great technical improvements in devices to measure DPA. Yet, 
subjective methods remain the primary approach in measuring PA in epidemiological studies.  
Their reports can be further validated through the use of objective measurements such as 
pedometers and accelerometers. However, in clinical research, where accuracy is important, 
objective methods such as pedometers, accelerometers, and accelerometers with physiological 
sensors may be better options (79). Besides, using both subjective and objective methods 
concurrently can be beneficial in obtaining more reliable results. Recently, studies have used the 
combination of short patient-reported questionnaires and two activity monitor variables to 
provide valid and reliable measures of PA in COPD patients (89).  
1.6.3.3 Levels of PA in COPD 
Due to its important implication in health outcome of COPD patients, there is a vast body 
of research on levels of DPA in COPD patients. The majority of the studies have focused on 
levels (90-94), duration (95-103) and intensity (95, 96, 98, 99, 102, 104, 105) of PA as well as 
overall activity counts (92, 93, 97, 100, 102, 106).  In general, they have documented a 
significant decrease in DPA in COPD patients compared to their healthy counterparts. Also, it is 
well documented that COPD patients spend more time sitting and lying down versus standing 
and walking in comparison to healthy elderly subjects (96, 107). Moreover, Pitta et al. (107) 
showed that COPD patients had significantly slower walking movement (lower intensity during 
walking) compared to healthy controls.  
 Additionally, this decrease in PA level is shown to progress across different stages of the 
disease and DPA is shown to have an inverse relationship with the disease severity (61, 92, 97, 
108). A recent 3-year longitudinal study on disease progression and changes in PA in COPD 
patients showed that, over time, PA decreases significantly from baseline across all stages of 
COPD (109). Moreover, Watz et al. (92) documented that the level of PA, number of steps per 
day, and minutes of at least moderate activity decreased across clinical stages of GOLD. The 
above variables also decreased from patients with chronic bronchitis to patients with stage IV 




inactive COPD patients increased in GOLD stage I, and BODE score 0, and the percentage of 
very inactive COPD patients increased in GOLD stage III and IV and BODE score 2 or more. 
Additionally, Troosters et al. (97) documented that number of steps per day as well as time spent 
at moderate PA levels decreases across all stages of COPD compared to healthy controls, with a 
significant decrease (p < 0.005) being reached as of GOLD stage II. It is also shown that number 
of steps per day, time spent walking, fast walking and total time walking decrease significantly 
across the GOLD stages II-IV, and a significant negative association between total walking time 
and GOLD stage (R=-0.35, P < 0.0001) is reported (108). Likewise, duration of PA and 
frequency of PA bouts were documented to decrease across GOLD stages (110). However, 
looking at time spent in vigorous PA, no significant difference was found between GOLD stages 
II-III and IV (102).  
Additionally, studies have examined the relationship between spirometry outcomes and 
daily PA to determine the significance of disease progression on levels of DPA. A majority of 
studies have examined the relationship between FEV1 % predicted and markers of PA, and a 
positive association between FEV1 % predicted and the following PA variables was documented: 
standing time per day (96), number of movement per day (r = 0.62, p<0.001) (111), leg activity 
(r = 0.57, p<0.001), time spent mobile (r = 0.51, p<0.01) (91), overall activity count (r = 0.41) 
(100) and daily levels of PA (109). Also, Hernandes et al. (96) documented a positive 
correlations between time spent standing  and FEV1/FVC and maximum voluntary ventilation 
(0.41< R <0.43; P < 0.05). Finally significant decrease in domestic PA is shown in patients with 
LTOT compared to patients without LTOT (p<0.001) (106).    
Furthermore, the association between PA and clinical characteristics and/or symptoms of 
COPD also has been investigated in multiple studies. Symptoms that are commonly examined 
are fatigue, dyspnea by MRC (Medical Research Council) scale, exercise tolerance capacity 
measured by the 6MWT. Measurements of clinical characteristics include BODE (a 
multidimensional composite measure of BMI, airway abstraction, dyspnea and exercise capacity) 
and quality of life mostly using Saint George’s Respiratory Questionnaire (SGRQ). Watz et al. 
(92) documented an inverse relationship between steps per day, PA levels and minutes of at least 
moderate activity and both BODE and MRC scores. They further documented that compared to 




BODE score 0 (patients who have the sensation of dyspnea on exertion) and the percentage of 
very inactive COPD patients increased in patients with BODE score 2 or more. Similar results 
were found by Jehn et al. (104), where total walking time and fast walking were significantly 
associated with BODE index > 6 (p=0.029 and p=0.040, respectively). In a recent study by Van 
Remoortel et al. (95), it was documented that patients with mild symptoms of dyspnea as well as 
low 6MWT and low maximal oxygen uptake had significantly lower physical activity levels. 
However, the study by Tabak et al. (105) found no significant relationship between physical 
activity levels with fatigue and dyspnea in this patient population. 
1.6.3.4 Diurnal Pattern of PA in COPD 
Extensive amount of research is conducted to evaluate PA levels in the general population 
as well as in COPD patients; however, not many studies have evaluated diurnal PA patterns not 
only in COPD patients, but also in the general population, young and old (112). Diurnal patterns 
have been observed in parameters of lung function (FEV1 and FVC), respiratory muscle strength 
(113), symptom perception (114), response to exercise testing (115) and to some extent in 
DPA(105). Moreover, while it is shown that symptom perception is worse in the morning, daily 
PA and parameters of pulmonary function have been shown to decrease in the evening (8:00-
5:00). Yet, the significance of various diurnal patterns of PA is not known. However, equally 
distributing daily PA is believed to improve patients’ management. Indeed, COPD patients are 
advised by healthcare professionals to balance their energy expenditure throughout the day by 
alternating heavy and light activities (105). Yet, there is no PA literature to support this 
recommendation. 
 Better understanding diurnal PA patterns in COPD patients could thus help optimize 
interventions targeting PA levels in this patient population. In the literature, studies examining 
diurnal PA patterns are scarce, both in the general population and in COPD patients. One study 
conducted in an elderly healthy population (mean age = 73 ± 3 years) showed that participants 
were mostly active from 6 to17h and that activity levels then decreased in the evening (116). In 
COPD patients, to our knowledge, only one study by Tabak et al. (105) evaluated diurnal 
patterns of PA. They too reported a significant decrease in activity levels from the morning (8-
13h) and afternoon (13-13h) to the evening (17-20h) in unemployed COPD patients (n = 32). 




(n = 7) and unemployed healthy controls (n = 10). Conversely, in employed healthy controls (n = 
11), they reported an “A-shape” pattern, where PA levels peaked in the afternoon, but were 
similar between morning and evening (105). Of note, the healthy control group in Tabak et al.’s 
study (105) was significantly younger than the COPD group. Overall, it is therefore difficult at 
this point in time to delineate the role of COPD per se versus factors associated with the disease 
(age, employment, etc.) on diurnal PA patterns 
Nevertheless, two methodological limitations related to PA monitoring may have affected 
their findings. First, the monitoring window in their study was relatively short (three-four days), 
and there was no mention of the respective contribution of weekend and weekdays. PA 
monitoring guidelines suggest a minimum of three-four days of monitoring with one weekend 
day to reach at least 80% of reliability; however, seven days of monitoring is preferred, as it 
represents the full week and allows for at least 90% of reliability (117). Another limitation of 
their study was the data handling approach used to determine onset, offset and splitting of the 
days. Indeed, an arbitrary handling approach was used, where day onset was fixed at 8:00, day 
offset was fixed at 20:00, and morning/afternoon/evening went from 8:00 – 13:00, 13:00 – 
17:00, and 17:00 – 20:00, respectively. This was the case for all participants, regardless of their 
individual daily routines. Hours outside the 8:00 – 20:00 window during which participants were 
awake were therefore excluded, and the different portions of the day were unequal in time and 
not representative of any particular event (e.g., meals). Additional research is warranted to 
further examine diurnal PA patterns in COPD patients using more empirical and ecological data 
handling approaches. Also, examining the link between PA patterns and other lifestyle factors 
may provide valuable insight for an optimal self-management 
1.7 Sleep in COPD 
 “Sleep is that golden chain that ties health and our bodies together” (Thomas Dekker, 
1572-1632). Sleep is needed as an essential part of human life to maintain physical and 
psychological health (118), as well as the body’s circadian rhythm (119). Sleep disturbances are 
associated with increased cardiovascular risk factors, stroke, type 2 diabetes, fatigue, lethargy, 
impaired cognition, and over all poor quality of life (120-122). Furthermore, the importance of 




Sleep has numerous effects on breathing such as changes in central respiratory control, 
lung mechanics and muscular contractility. The above changes are harmless and do not effect 
healthy individuals, but could impact COPD patients by resulting in significant hypoxemia and 
hypercapnia, particularly during rapid eye movement (REM) (124). Healthy subjects may also 
experience some mild hypoxemia, which is the result of trivial hypoventilation.  However, this 
may become worse in COPD patients due to other factors impacting hypoventilation, such as air 
way obstruction, muscle dysfunction and diminished respiratory drive in addition to ventilation-
perfusion mismatching (V’/Q’)(118) and some COPD medications (125).  
1.7.1 Measurements of Sleep in COPD 
Similar to PA, sleep can also be assessed both subjectively and objectively. Subjective 
methods include questionnaires and self-report methods. As mentioned in the PA measurement 
section, subjective assessment methods are based on individual patient’s recollection and 
judgment; therefore, it could be impacted by recall bias. On the other hand, objective measures 
provide more precise and detailed information, not only about sleep duration, but also sleep 
architecture, such as different sleep stages (non rapid eye movement: NREM or rapid eye 
movement: REM, slow wave sleep: SWS), amount of time awake during sleep periods, and 
frequency and duration of wake times after sleep onset (126). Objective assessment tools include 
polysomnagraphy (PSG), which is the gold standard for sleep measurement, and activity 
monitors/accelerometers, frequently referred to as actigraphy (127). Even though PSG is the gold 
standard and provides extensive details about sleep behaviour of an individual, it is also very 
expensive and can be too invasive to be used in clinical studies, especially when the primary 
focus of the study is sleep and/or wake duration (128).  On the other hand, actigraphy is simple, 
inexpensive and less time consuming compare to PSG and it is independent of patients’ ratings 
and personal judgments of their sleep. Additionally, actigraphy has been validated for sleep 
against PSG in young and older subjects, in healthy and in chronic primary insomniac patients, 
with overall high sensitivity (0.965) and accuracy (0.863), but low specificity (0.329) (129). 
Actigraphy provides estimates of sleep/wake schedules based on differences in movements 
associated with wakefulness or sleep (128), and position of the body (lying down).  Further, 
actigraphy can conveniently allow for 24-hour continuous data monitoring for multiple days, 




studies have used reliable subjective (131) and objective (131, 132) methods to assess sleep 
quality in COPD patients.  
1.7.2 Sleep Related Disturbances in COPD  
Disturbed sleep is common in COPD patients (124, 133) and it is one of the most common 
symptoms reported in this patient population (125). It is suggested that around 40% of COPD 
patients report disturbed sleep (134) and a majority of COPD patients have sleep efficiency in 
the range of 50-70% (125). Moreover, COPD patients have difficulty falling and/or staying 
asleep, more light sleep and less deep sleep (REM), increased micro arousals and recurrent shift 
between sleep stages (125). COPD patients report diverse sleep disorders such as insomnia and 
obstructive sleep apnea, and sleep related disturbances such as sleep related hypoxemia, sleep 
hypoventilation, and restless leg syndrome (135).   
Insomnia is characterized by difficulties falling and/or staying asleep, waking up too early 
or having un-refreshed sleep (135). Budhiraja et al. (131) documented that the prevalence of 
insomnia is three-fold higher in COPD patients compared to the general population.  They 
further reported a higher prevalence (27.3 %) of insomnia, which was defined as chronic sleep 
disturbances related with impaired daytime functioning in COPD patients. In the same cohort, 
they reported actigraphy-measured shorter sleep duration and lower sleep efficiency in COPD 
patients with insomnia compared to those without it.  In another study they showed that the 
presence of COPD was significantly associated with increased odds of insomnia 1.9 (1.5–2.5, p 
< 0.001) (136). They further reported low sleep efficiency (<82%) in a larger proportion (44%) 
of COPD patients compared to individuals without COPD (31%). Another study documented 
that frequency of insomnia was higher in COPD patients compared to healthy controls (47.2 % 
and 25.7 %; respectively). However, they also reported that 21.3 % of the variance between the 
groups was due to more physical illnesses and depressive symptoms in COPD patients (137). 
Similar results were shown in a more recent study, where prevalence of insomnia was 48.1% in 
COPD patients compared to 27.6 % in healthy controls (138).  
Also, the association between COPD severity and prevalence of insomnia is not clear 




and they documented a significant association between sleep disturbances (difficulty falling 
asleep, night time awakenings, morning fatigue, and sufficiency of sleep duration) and patients’ 
symptoms such as cough (p = 0.034), and dyspnea (p = 0.004) (123).  They also reported 
increased likelihood of sleep disturbances with greater disease severity (p = 0.015), whilst 
another study did not find a significant association between FEV1 and insomnia symptoms (131). 
Obstructive sleep apnea (OSA) is a chronic sleep disorder, which is characterized by 
repeated episodes of upper airway collapse during sleep, influencing night time sleep quality and 
daytime fatigue and sleepiness (139). Prevalence of OSA in COPD is considered to be similar to 
that of the general population (about 10 to 30%) (140-142). Moreover, both OSA and COPD are 
common pulmonary disorders and prevalence of their coexistence is about 1% in the general 
population (143), which is called overlap syndrome.  However, it is also shown that sleep 
disordered breathing is more severe when it coexists with COPD (140).  Among other factors, 
decreased exercise capacity can lead to obesity and muscular deconditioning, which in turn may 
lead to increased upper airway collapsibility. These are considered to be plausible factors in 
increasing occurrence of overlap syndrome (135) 
Sleep related abnormalities and primary sleep disorders that are frequently associated with 
COPD thus include insomnia, OSA, restless leg syndrome, sleep related hypoxemia,  and sleep 
hypoventilation. Co-occurrence of the above factors with COPD may further deteriorate the 
quality of life of COPD patients by increasing risks of other health conditions (i.e. depression, 
anxiety, panic attack, severe and/or chronic pulmonary hypertension) including increased 
mortality rate of up to 7-fold (135).  
1.8 Association between PA and Sleep in Older Adults 
Both PA and sleep are important health related lifestyle factors that decrease with age, and 
remain modifiable well into the later life (144). More recently, evidence has suggested a possible 
reciprocal relationship between these two lifestyle factors (145-148).  Epidemiological studies 
consistently suggest that both acute and chronic exercise improve sleep, such that greater levels 
of PA are associated with better outcomes in sleep measurements (149). Similarly, some clinical 




studies, King et al. (150, 151) reported a positive association between exercise and both 
objectively (PSG) and subjectively (self-reported) measured sleep quality in individuals with 
poor sleep. Likewise, two meta-analyses reported modest improvement in several sleep 
parameters including total sleep time (TST), slow wave sleep and REM sleep latency after an 
acute bout of exercise (149, 153). Similarly, another study in women with insomnia reported that 
TST, sleep efficiency (SE) and self-reported global sleep quality improved after 16 weeks of 
exercise, and exercise session duration was negatively associated with ratings of sleepiness at 
baseline (147).  It is suggested that no improvement (154) or modest improvement observed in 
sleep could be due to healthy subjects with good sleep quality (154).  
However, studies examining the association between DPA and sleep parameters are scarce 
and have contradictory findings.  Whereas, a longitudinal and cross sectional study with 14,001 
older adults documented an inverse association between habitual PA and both prevalence and 
incidence of insomnia, particularly improved the ability to stay asleep (146). Similarly, better 
initial sleep quality was shown to project greater levels of PA, beyond the effects of initial PA 
levels in a 2-year longitudinal study in healthy older adults. However, the initial PA levels did 
not predict later sleep quality after adjusting for prior sleep quality (145).  Conversely, other 
studies have documented no association between PA and sleep in older women (148) and normal 
sleepers (154).  
The temporal relationship between PA and sleep parameters has also been examined and 
certain associations between them are documented. One study with subjective reports of sleep in 
women with insomnia reported that poor sleep quality on a given night was associated with 
shorter exercise duration the following day, but exercise duration during the day did not predict 
next night sleep quality (147). Another study in older women with objective measurements of 
both sleep and PA reported two small findings: 1) they documented that greater daily PA and 
more minutes of moderate to vigorous PA were temporally associated with less TST the 
following night. 2) Higher SE and less sleep fragmentation were associated with greater PA 
counts and more minutes of moderate to vigorous PA the following day (148).  
Moreover, the reciprocal relationship between PA and sleep is documented in the general 




significant predictor of next day PA, such that nights with good sleep quality was followed by 
days with greater PA, especially between noon to 11PM (155). In addition, a review article on 
the The Role of Sleep and Physical Activity on the Risk for Cardiovascular Disease highlighted 
the importance of considering poor sleep quality as a barrier to the maintenance of regular PA 
(156) (Appendix A). Similarly, in COPD patient, one study documented a significant inverse 
correlation between functional exercise capacity (as measured by the six-minute walk test) and 
subjective sleep quality (157). Yet, to our knowledge, the relationship between daily PA and 
sleep has never been investigated in this patient population. 
In summary, increased regular PA is shown to be associated with improved sleep 
parameters and over all better sleep quality. Therefore, increased and regular PA may have more 
importance for individuals with poor sleep quality than normal sleepers. Further, sleep quality 
can also impact PA levels in both long and short-term periods, which could be an important 
factor in individuals with reduced PA levels.  
1.8.1 Possible Mechanisms for the Association between PA and Sleep 
There are some suggested mechanisms through which these two lifestyle factors may 
influence each other. The recent review by Chennaoui et al. (158) summarizes the suggested 
mechanisms in two diagrams. According to their review, acute moderate-intensity aerobic 
exercise affects core body temperature, the endocrine system and metabolism (increase growth 
hormone, and decrease insulin sensitivity), and inhibits some parts of autonomic nervous system 
(ANS). On the other hand, regular moderate-intensity aerobic PA affects all of the above in 
addition to the immune inflammation response during sleep, mood and possibly circadian 
rhythm. From the above changes, core body temperature is shown to be inversely associated 
while circadian rhythm and mood are shown to be directly associated with improved sleep time 
and slow wave sleep. Further, changes in the endocrine system and metabolism, ANS and 
immune-inflammation response during sleep may also be related with improved sleep time and 
slow wave sleep.  
Sleep loss is considered to have substantial psychological affects; however the effect of 




their review, Chennaoui et al. (158) summarized that acute sleep loss may disturb metabolism 
(increase insulin resistance) and immuno-inflammation response, and chronic sleep loss may 
affect central nervous system (CNS), endocrine system (increase cortisol, decrease growth 
hormone) and ANS (increase sympathetic activity). Through more complex pathways, the above 
changes may further affect alertness, mood, articular and muscle repair, coronary arterial tonus 
and heat tolerance, which may further cause reduced physical performance, reduced recovery 











2.0 Rationale  
The literature widely suggests that physical activity and exercise training have many 
benefits for the physical and psychological well-being of an individual (159). However, COPD 
patients are often too limited by their symptoms to stay active (160). Even regular daily activities 
can become unsustainable due to increasing levels of dyspnea, eventually leading to further 
inactivity (161). This subsequently leads to muscular deconditioning, creating a vicious cycle 
that can quickly and severely deteriorate the quality of life of COPD patients (161). It has been 
shown that increased physical activity is directly associated with a reduced rate of hospital 
admission and increased survival rate in this patient population (66). Therefore, the evaluation of 
PA levels in COPD patients has become an important area of research in the past decades.  
As documented in an earlier section (Levels of PA in COPD), levels of PA have been 
consistently shown to be significantly lower in COPD patients compared to healthy controls. 
However, there is a scarcity of literature on diurnal PA patterns in the general population as well 
as in COPD patients. Yet, equally distributed daily PA is believed to improve patients’ 
management. Indeed, COPD patients are advised by healthcare professionals to balance their 
energy expenditure throughout the day by alternating heavy and light activities (105). There is 
currently no PA literature to support this recommendation. Better understanding diurnal PA 
patterns in COPD patients could help optimize interventions targeting PA levels. 
As discussed previously (Sleep in COPD), disturbed sleep is another common feature in 
COPD patients (124, 133) and it is the third most frequently reported symptoms after dyspnea 
and fatigue (125). Recent evidence has suggested a possible reciprocal relationship between 
physical activity and sleep in the general and elderly populations (145-148). However, to our 
knowledge, the potential association between daily PA and sleep has never been investigated in 
COPD patients. Exploring links between these two modifiable lifestyle factors may provide 










3.0  Research Objectives and Hypotheses  
3.1 Research Objective  
I. To characterize, in COPD patients, diurnal patterns of objectively assessed PA from 
morning to afternoon to evening using three different splitting approaches (arbitrary, 
mealtime, equal tertiles).  
II. To characterize objectively measured sleep quality in COPD. 
III. To explore the association between daily PA and sleep quality parameters in COPD.  
3.2 Research Hypotheses 
I. Based on earlier findings from Tabak et al. (105), we hypothesized that mean PA level 
would decrease throughout the day, from morning to afternoon to evening. The 
comparison of the different splitting approaches was exploratory since no earlier 
comparisons were available in the literature. 
II. Based on previous findings from Nunes and colleagues (162), we hypothesized that 
sleep parameters would indicate poor sleep quality (mainly a low SE, defined as a SE 
< 84%) in our convenient sample of COPD patients,  
III. Based on the existing literature (149), we hypothesized that there would be a 
significantly positive association between daytime PA level and sleep quality in our 
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4.1 Abstract  
Background: Extensive evidence has documented reduced physical activity (PA) levels, 
duration, and intensity in COPD patients compared to healthy controls. In return, diurnal PA 
patterns have rarely been studied. Better understanding diurnal PA patterns could help optimize 
interventions targeting PA levels. Also, examining links between PA patterns and other lifestyle 
factors may provide valuable insight for an optimal self-management. Disturbed sleep is another 
common feature in COPD and one of the symptoms most frequently reported by patients. Recent 
evidence in poor sleepers has suggested a possible reciprocal relationship between PA and sleep. 
This relationship has not, to our knowledge, been investigated in COPD patients. The aims of the 
present study were: i) to characterize, in COPD patients, diurnal patterns of objectively assessed 
PA from morning to afternoon to evening using three data handling approaches (arbitrary, 
mealtime, equal tertiles); ii) to characterize objectively measured sleep quality in COPD; and iii) 
to explore the association between daily PA and sleep quality parameters in COPD. 
Methods: Fourteen COPD patients (aged 71 ± 9 years) with mostly moderate COPD 
(FEV1: 58 ± 13 % predicted) participated in the study. Daily PA and sleep characteristics (Sleep 
Onset Latency [SOL], Wake After Sleep Onset [WASO], Total Sleep Time [TST], Sleep 
Efficiency [SE%] and Fragmentation Index [FI]) were assessed via actigraphy for 7-consecutive 
days, 24 hours/day. Daily PA was computed from rise time to bedtime (except for the arbitrary 
approach), while sleep characteristics were computed from bedtime to rise time. Diurnal PA 
patterns were evaluated by breaking down daily PA into three portions using an arbitrary 
approach (8:00-12:00, 12:01-16:00, 16:01-20:00), a mealtime approach (wake time- lunchtime, 
lunchtime- suppertime, suppertime- bedtime) and an equal tertiles approach (1st Tertile, 2nd 
Tertile and 3rd Tertile). The interaction effect of period of the day (morning, afternoon and 
evening) by handling approach (arbitrary, mealtime, and equal tertiles) on PA level was 
examined with two-way repeated-measures ANOVA using the General Linear Model. This was 
followed, if needed, by simple main effect tests (ANOVAs) of period of the day effect for each 
handling approach, and pairwise comparisons with Bonferroni corrections to compare PA levels 
between different periods of the day. Associations between mean 7-day/night sleep parameters 




deviation (SD) of PA level (as a measure of daily PA variability) were assessed with Pearson’s 
or Spearman’s correlations, depending on data distribution and sample size.  
Results: There was a significant interaction effect of period of the day by handling 
approach on PA level (F 2.77, 36.03 = 18.01, p < 0.001). Regardless of the data handling approach, 
a significant difference in activity count was observed between the different portions of the day, 
mean PA levels particularly dropping in the evening (F2, 26 = 6.63, p < 0.005 for the arbitrary 
split, F2, 26 = 23.06, p < 0.001 for the mealtime split, F2, 26 = 22.16, p < 0.001 for tertile split). 
This observation was homogeneous across our sample, but less evident with the arbitrary 
approach. Participants had, on average, a SOL of 22 ± 17min, WASO of 65 ± 29 min, TST of 
383 ± 59 min, SE of 79 ± 9 % and FI of 45 ± 23 %. Sleep quality parameters showed very weak 
to weak associations with mean daily PA, very weak to moderate associations with PA in each 
portion of the day, and weak to strong associations with daily PA variability (correlation 
coefficients ranging from -0.50 to 0.42 across the different variables).  
Conclusion:  Results from this study support prior findings that PA levels decrease 
significantly in the evening compared to both morning and afternoon in COPD patients. They 
further suggest that the data handling approach used to evaluate diurnal PA patterns may affect 
the extent of the decrease observed. Based on the mean values obtained for SE, WASO, and 
SOL, some degree of sleep disturbances may be present, even in patients with moderate COPD. 
The association between PA and sleep quality parameters appears to be weak in this subset of 
patients compared to what was previously shown in “healthy” poor sleepers, but the PA-sleep 
relationship will have to be further investigated in COPD patients.  




4.2 Introduction  
Chronic Obstructive Pulmonary Disease (COPD), is a preventable and manageable chronic 
lung disease characterized by partially irreversible obstruction and/or inflammation of the 
airways (11, 20, 51). It encompasses a cluster of respiratory diseases, which include mainly 
chronic bronchitis and emphysema(51). As a result of either process, the ability to breathe 
normally is decreased due to obstructed airflow related to excessive mucosal secretion and 
inflammation, the loss of elasticity of the bronchioles and alveoli, and/or damaged lung tissue 
(28). The progression of COPD often follows a downward spiral, which begins with airflow 
limitation and dyspnea, followed by inactivity and muscular deconditioning, leading to a 
worsening of the dyspnea sensation and eventually to invalidity and poor quality of life. 
Levels of daily physical activity (PA) have been shown to drop substantially with age 
among the healthy elderly population, particularly after the age of 74 years (57). The decrease in 
PA levels becomes a more serious situation in COPD patients, as it has been shown that 
inactivity worsens their physical condition and may further increase their sensation of dyspnea 
(163, 164); however, it is not clear to what degree inactivity affects the progression of COPD 
(57). Physical inactivity is directly associated with patient’s perception of dyspnea (58), and the 
sensation of dyspnea is disproportionally greater with decreases in lung function in inactive 
patients compared to active patients(58). Due to its significant impact on patients’ physical 
condition and symptom perception, PA has become a valued outcome measure in COPD 
patients.  
In the past decades, a vast body of evidence has suggested that levels (90-94), duration (95-
102, 165) and intensity (95, 96, 98, 99, 102, 104, 105) of PA, as well as overall activity counts 
(92, 93, 97, 100, 102, 106) are significantly decreased in COPD patients compared to healthy 
subjects, which in most cases were matched for age, sex and body mass index (BMI). Much less 
studied, diurnal patterns of PA (i.e. time-of-day evolution of PA) may also warrant some 
consideration in COPD patients. Within-day variations in lung function parameters (FEV1 and 
FVC), respiratory muscle strength (113), symptom perception (114), and response to symptom-
limited incremental cardiopulmonary exercise testing (115) have been documented in COPD 




others (e.g., pulmonary function, exercise response) seem to rather dip in the afternoon or 
evening, at least in certain subsets of patients (113-115). In a relatively recent study, Tabak et al. 
(105) documented a significant decrease in PA throughout the day from morning to afternoon to 
evening, particularly in unemployed COPD patients (n = 32). Employed COPD patients (n = 7) 
and unemployed healthy controls (n = 10) displayed a similar pattern, but the drop in PA was not 
statistically significant in those subgroups, possibly because of their small sample size. In return, 
employed healthy controls (n = 11) exhibited a different “A-shape” pattern, where PA peaked in 
the afternoon and was similar between morning and evening. 
To our knowledge, Tabak et al.’s study (105) is the only one available to date on diurnal 
PA patterns in COPD patients. There is also a paucity of literature on this topic in the general 
population, young and old (112). Therefore, the significance of various diurnal patterns of PA is 
not known. In COPD patients, equally distributing daily PA is believed to improve their 
management. Indeed, COPD patients are advised by healthcare professionals to balance their 
energy expenditure throughout the day by alternating heavy and light activities (105). Yet, there 
is no PA literature to support this recommendation. Better understanding diurnal PA patterns in 
COPD patients could thus help optimize interventions targeting PA levels in this patient 
population. In this respect, Tabak and colleagues (105) made a landmark contribution to the 
COPD literature with their study. Nevertheless, two methodological limitations related to PA 
monitoring may have affected their findings.  
First, the monitoring window in their study was relatively short (three-four days), and there 
was no mention of the respective contribution of weekend and weekdays. PA monitoring 
guidelines suggest a minimum of three-four days of monitoring with one weekend day to reach 
at least 80% of reliability; however, seven days of monitoring is preferred, as it represents the 
full week and allows for at least 90% of reliability (117). Another limitation of their study was 
the data handling approach used to determine onset, offset and splitting of the days. Indeed, an 
arbitrary handling approach was used, where day onset was fixed at 8:00, day offset was fixed at 
20:00, and morning/afternoon/evening went from 8:00 – 13:00, 13:00 – 17:00, and 17:00 – 
20:00, respectively. This was the case for all participants, regardless of their individual daily 
routines. Hours outside the 8:00 – 20:00 window during which participants were awake were 




representative of any particular event (e.g., meals). Additional research is warranted to further 
examine diurnal PA patterns in COPD patients using more empirical and ecological data 
handling approaches. Also, examining the link between PA patterns and other lifestyle factors 
may provide valuable insight for an optimal self-management.  
Disturbed sleep is another common feature in COPD patients (124, 133) and it is one of the 
most frequently reported symptoms in this patient population (125). It has been suggested that 
around 40% of COPD patients report disturbed sleep (134, 166) and that a majority of patients 
have a sleep efficiency (SE) ranging from 50 to 70% (125), versus 84 % or more in healthy older 
adults (167, 168). Additionally, COPD patients are known to have difficulty falling and/or 
staying asleep, more light sleep and less deep sleep (REM), increased micro arousals, and 
recurrent shift between sleep stages (125). COPD patients exhibit diverse sleep disorders, such as 
insomnia and obstructive sleep apnea, and sleep-related disturbances, such as sleep-related 
hypoxemia, sleep hypoventilation, and restless leg syndrome (135).   
Both PA and sleep are important health-related lifestyle factors that demonstrate significant 
decrease with age, but remain modifiable well into later life (144). More recently, evidence has 
suggested a possible reciprocal relationship between these two lifestyle factors (145-148). 
Positive associations between exercise training and both objectively (polysomnography, PSG) 
and subjectively (self report) measured sleep quality have been documented in individuals with 
poor sleep (150, 151). Furthermore, habitual PA has been associated with lower prevalence and 
incidence of insomnia, and more precisely with an improved ability to stay asleep in healthy 
elderly adults (146). In COPD patients, one study documented a significant inverse correlation 
between functional exercise capacity (as measured by the six-minute walk test) and subjective 
sleep quality (157). Yet, to our knowledge, the relationship between habitual PA and sleep has 
never been investigated in this patient population.  
The aim of this project was to examine habitual PA and sleep in COPD patients and explore 
the potential association between these two lifestyle factors. More specifically, our objectives 
were: i) to characterize, in COPD patients, diurnal patterns of objectively assessed PA from 




equal tertiles); ii) to characterize objectively measured sleep quality in COPD; and iii) to explore 
the association between daily PA and sleep quality parameters in COPD.
4.3 Methodology  
4.3.1 Study Design and Participants  
This study is a secondary analysis of data collected during an observational prospective 
pilot project on The Impact Of Time-Of-Day On The Acute Response To Incremental Exercise In 
COPD Patients (169). The project was conducted between August 2010 and April 2011 in a 
convenience sample of 14 individuals with COPD recruited from Hôpital du Sacre Coeur de 
Montréal, in Quebec, Canada. Inclusion criteria were: 1) clinically stable COPD; 2) age ≥ 40 
years; 3) smoking history ≥ 10 pack-years (20 cigarettes/pack); 4) a post-bronchodilator FEV1 of 
less then 80% of the normal predicted value; 5) a ratio of FEV1 over forced vital capacity (FVC) 
of less than 0.7; 6) previous experience of exercise testing. Exclusion criteria were: 1) a 
respiratory exacerbation in the past 4 weeks; 2) contraindications to exercise testing based on 
guidelines from the American Thoracic Society (4); 3) need for oxygen therapy; 4) any 
secondary condition other then COPD (e.g., asthma, severe arthritis, unstable coronary heart 
disease, left congestive heart failure, serious psychiatric comorbidity) that could affect measured 
outcomes; and 5) prescribed theophylline.  
As part of the broader project, upon obtaining medical clearance for exercise testing, 
participants came to the research center for a total of four visits. During the first visit, 
demographics and clinical information such as age, sex, height, weight, and body mass index 
(BMI) were obtained and baseline spirometry was performed. During the same visit, subjects 
were also familiarized with the testing equipment and procedures. Visits 2-4 (each separated by 
> 36 hours) were meant to serve the abovementioned project on time-of-day variations in acute 
response to incremental exercise (170). Throughout the study, which lasted a minimum of 7 days 
and maximum of 14 days, participants were instructed to wear the Actiwatch on their non-
dominant wrist every day, 24 hours/day. They were asked to keep the device free of clothing and 
to remove it while taking a shower or swimming, and when participating in activities that 




monitoring period and to press the event marker button on the watch to mark bedtime and rise 
time. For the duration of the study, subjects also completed a journal of their physical activity, 
meal times, sleep habits, and mood.  
4.3.2 Assessments 
4.3.2.1 Pulmonary Function Test  
Baseline pulmonary function measures were obtained from the spirometry conducted 
during Visit 1, which was performed according to recommended techniques (171) . Predicted 
normal values from the European Community for Coal and Steel/ European Respiratory Society 
were used for comparison of obtained values to reference values (171). 
4.3.2.2 Actigraphy 
Hardware  
 The Actiwatch (Actiwatch‐ 2, Respironics, Bend, USA) is a wristband accelerometer with an 
activity sensor consisting of a miniature piezo-electric transducer (172). The activity sensor 
produces a voltage, which is then amplified, digitized, and recorded as an activity count (172) 
shown to be both reliable and valid in its measurements (170). The device is also equipped with a 
light-sensor. The Actiwatch is light (16g with the band, 43 x 23 x 10mm) and measures activity in all 
dimensions.  The device has a sensitivity of 0.025 g-force (g) (at 2 count level) with peak values 
between 0.5-2g, a sampling rate of 32 Hertz, and a bandwidth of 0.32-7.5 Hertz. It is most often used 
for sleep/wake analysis; therefore consistency of the activity count at the low end (lower then 100 
counts) is very good (172).  It thus seems suitable for COPD patients who are typically older and 
more sedentary than healthy population. Additionally, Actiwatch has been validated for sleep 
assessment against PSG in young and older subjects, healthy and chronic primary insomniac 








The actigraphy data were analyzed with the Actiware software version 6.01 (MA, USA). 
The software identifies each epoch as sleep/wake using mathematical algorithm developed 
previously (173). Different wake thresholds can be set in order to score an epoch as sleep or 
wake. Epochs with activity counts equal or bellow the chosen thresholds are considered as sleep, 
while those with a count above the chosen threshold are considered as wake.  The software 
threshold selections available are: i) low (20 counts per epoch; high sensitivity), ii) medium (40 
counts per epoch; medium sensitivity), iii) high (80 counts per epoch; low sensitivity), and iv) 
automatic (i.e. computed automatically based on activity counts of the day). There are no 
specific recommendations by the manufacturer for different thresholds, but medium threshold is 
commonly used, such that this is what was applied in our study. The calculation for each 1 
minute epoch is done according to the following formula: � = ሺ�′ͳሻ ቀଵ5ቁ + ሺ�′ʹሻ ቀ ଵଶ5ቁ + �� +�ʹ ቀ ଵଶ5ቁ + �ͳ ቀଵ5ቁ.  �′ͳ and �′ʹ are the activity counts from prior 1-minute and 2-minute of the 
epoch being scored, and �ͳand �ʹ are the subsequent 1-minute and 2-minute, respectively. 
Figure 5 illustrates how this calculation is done.  
          
        Figure 4 - Calculation to score a minute as wake or sleep 
4.3.3 Data Handling 
All data points were visually inspected for missing data. Bedtimes and wake times were 
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output.  Each line is a 24-hour period with yellow sections representing time out of bed, blue 
sections representing time in bed, and black spikes representing activity epochs. Bedtime was 
determined by comparing bedtime markers against the information provided in the journal, and 
the activity count data. The investigator’s marker was placed where two of the three methods 
best matched. Similar method was used to determine wake time. The small blue markers on 
Figure 6 show bedtime and rise time.  
 
 
Figure 5 - Screen Shot of an Actiwatch-2 Output 
4.3.3.1 Data Handling for Physical Activity Measures  
Physical activity data was analyzed from wake time to bedtime for seven consecutive valid 
days. Based on a systematic review article entitled “A Catalogue of Rules, Variables, and 
Definitions Applied to Accelerometer Data in the National Health and Nutrition Examination 
Survey” (174), the following set of rules were applied. Periods with more than 60 min of 
consecutive zeros were considered as non-wear time and excluded from analyses, in addition to 
non-wear time recorded in the participants’ journals. A valid day was defined as a day with at 
least 10 hours of physical activity data. In addition, for the present study, if three or more 
consecutive hours of data were missing in a given day, the day was excluded from analyses. This 





To address our first objective (characterization of diurnal PA patterns), valid days were 
split in three parts using three different approaches: 1) an arbitrary approach, as used in previous 
studies (105), in which daily PA was extracted from 8:00 to 20:00 and divided into morning 
(8:00-12:00), afternoon (12:01-16:00), and evening (16:01-20:00); 2) a mealtime approach, in 
which daily PA was extracted from rise time to bedtime and divided based on the meal times 
reported by participants in their journals (wake time to lunch time [WT-LT], lunch time to 
supper time [LT-ST] and supper time to bedtime [ST-BT]); and 3) a tertiles approach, in which 
daily PA was extracted from wake time to bedtime and divided into three equal tertiles (tertiles 
1, 2, and 3, respectively).   
4.3.3.2 Data Handling for Sleep Measures  
Sleep characteristics were computed from bedtime to wake time for 7 consecutive valid 
nights. Nights with 180 minutes or more of consecutive zeros were excluded, as this time was 
considered non-wear time based on previous study (175). Sleep onset was determined by the 
software algorithm as the first 10 minutes of consecutive zeros after bedtime and labeled as the 
first sleep epoch. This process continued until the last epoch, which was labeled as sleep offset 
(or wake time). For our second objective (characterization of sleep), the following sleep quality 
parameters were calculated: (1) time in bed (TIB; period going from bedtime to the following 
wake time; 2) total sleep time (TST; total number of epochs between sleep onset and sleep offset 
or wake time scored as sleep by the software); 3) sleep onset latency (SOL; interval from 
bedtime to sleep onset in minutes); 4) sleep efficiency (SE; total sleep time/ time in bed X100); 
5) fragmentation index (FI; measure of restlessness calculated from percent mobile and immobile 
bouts, with higher values signifying poor sleep continuity). Figure 7 summarizes computation of 





Figure 6 - Computation of Sleep Characteristics 
4.3.4 Statistical Analysis 
The normality of the distribution of the studied outcomes was verified using measures of 
skewness and kurtosis. For our first objective, which was to characterize daily PA patterns 
according to three different handling approaches, descriptive analyses (mean ± standard 
deviation [SD]) were conducted for individual participants and for the group. Moreover, the 
interaction effect of periods of the day (independent variable #1 with three levels: morning, 
afternoon and evening) by handling approach (independent variable #2 with three levels: 
arbitrary, mealtimes, and equal tertiles) on PA level (dependent variable) was examined with 
two-way repeated-measures ANOVA using the General Linear Model. This was followed, if 
needed, by simple main effect tests (ANOVA) of the period of the day effect on PA level for 
each handling approach separately. Huynh-Feldt corrections for Sphericity were applied for 
analysis on more than two levels, but original degrees of freedom are reported. Pairwise 
comparisons with Bonferroni adjustment were then conducted in cases where a significant period 
of the day effect was detected with the ANOVA to identify between which levels the 
difference(s) in PA levels occurred. The effect size (Cohen’s f) was calculated and interpreted 
according to the established methods (small: 0.1; medium: 0.25; large >0.4) (176).  
For our second objective, which was to characterize sleep, descriptive analyses (mean ± 
standard deviation [SD]) were conducted for individual participants as well as for the group. For 




bivariate correlations were conducted between sleep parameters and daily PA, PA in each tertile 
of the day, and inter-tertile SD of PA using either Pearson r or Spearman rho, depending on the 
distribution of the data. Lastly, exploratory scatterplots were done to examine temporal 
relationship between daily PA and sleep parameters (SOL, WASO, TST, SE, and FI) for each 
monitoring day with its corresponding night for each participant.  All statistical tests were two 
tailed and conducted at p ≤0.05. The statistical analyses were performed with SPSS version 18.0 
(Chicago, IL). 
4.4 Results  
Fourteen participants (9 men, 5 women) with moderate (n = 12) to severe (n = 2) airflow 
obstruction (FEV1: 58 ± 13% of the normal predicted value, see appendix for FEV1 distribution) 
completed the study. Upon examination of the age distribution, two distinct subgroups emerged 
as shown in Figure 8: a subgroup of younger-old participants aged 58-67 years and a subgroup of 
older-old participants aged 74-79 years. The younger-old subgroup consisted mostly of females 
(5/6) while the older-old subgroup was composed entirely of males (8/8). Given the documented 
impact of age on both PA and sleep (177, 178), this feature was considered in subsequent results.  
Baseline characteristics of the sample are presented in Table 2. Of note, only one participant had 
diagnosed obstructive sleep apnea and other participants had no diagnosed sleep disorder. 
 
Figure 7 – Age distribution of the sample. Each marker represents one participant. Line and bar represent Mean ± SD 
 
 






Table 2 - Baseline Characteristics of Sample and Age Subgroups 
Characteristics  Full Samples Younger-old Older-old 
n     14      6       8 
Age (yr)     71 ± 7      64 ± 3      77 ± 2 
Sex (male/female)     9/5      1/5      8/0 
BMI (kg/m2)     27 ± 4      26 ± 5      27 ± 3 
Smoking status (current, n)     2      1      1 
FEV1 (% Pred)     58 ± 13      56 ± 17      59 ± 10 
FEV1 /FVC (%)     53 ± 11      54 ± 9      52 ± 12 
Wake Time  7:08 ± 0:46   6:45 ± 0:38   7:23 ± 0:47 
Bedtime 22:51± 0:39 23:04 ± 0:38 22:41 ± 0:37  
Sleep Efficiency (%)     79 ± 9      80 ± 9      76 ± 10 
Daily PA (cpm)   250 ± 60    287 ± 64    222 ± 41 
Values are Mean ± SD unless otherwise stated. BMI: body mass index; FEV1: forced expiratory volume in 
1sec; FVC: forced vital capacity; PA: physical activity, cpm: counts per minute. 
4.4.1 Diurnal Physical Activity Pattern 
Physical activity data were normally distributed. Table 3 presents PA levels for the 
different portions of the day according to the three splitting approaches. There was a significant 
interaction effect of period of the day (morning, afternoon and evening) by handling approach 
(arbitrary, mealtime, and equal tertiles) on PA level (F 2.77, 36.03 = 18.01, p < 0.001). Follow-up 
ANOVAs indicated a significant difference in activity count between the different portions of the 
day regardless of the splitting approach (F2, 26 = 6.63, p < 0.005 for the arbitrary split, F2, 26 = 
23.06, p < 0.001 for the mealtime split, F2, 26 = 22.16, p < 0.001 for tertile split) and large effect 
sizes (f = 0.45, 0.83, and 0.74 for the three approaches, respectively). For the arbitrary split, 
pairwise comparisons further revealed that the decrease was significant between morning and 
evening only (p < 0.05) and not between morning and afternoon (p = 0.204) or afternoon and 
evening (p = 0.148). For both mealtime and tertile split, pairwise comparisons showed that the 
difference in PA levels was significant between the first and third portions of the day (p <0.001) 
and between second and third portions (p < 0.05), but not between first and second portions (p = 
1.0). Since results for mealtime and equal tertiles splits were very similar, further results are 




Table 3 - PA Levels (Mean ± SD) for Different Portions of the Day According to Three Splitting 
Approaches 
Arbitrary Split 
   Morning (8:00-12:00) 301 ± 92 
Afternoon (12:01-16:00) 277 ± 84 
Evening (16:01-20:00) 238 ± 58* 
Mealtimes  
   WT-to-LT (7:08-12:25) 293 ± 76 
LT-to ST (12:26-16:59) 280 ± 85 
ST-to-BT (17:00-22:51) 165 ± 59** 
Equal Tertiles 
   1st Tertile (7:08-12:22) 288 ± 75 
2nd Tertile (12:23-17:37) 285 ± 90 
3rd Tertile (17:38-22:51) 176 ± 51** 
WT: wake time; LT: lunchtime; ST: suppertime; BT: bedtime. *p < 0.05 vs morning PA, **p < 0.001 vs morning 




Table 4 presents mean 7-day count for daily PA and for each tertile of the day, as well as 
inter-tertile SD (as a measure of variability) for each of the 14 participants. The two most active 
individuals are in blue; they also had the highest inter-tertile SD of the group. The two least 
active individuals are in red. Figure 9 illustrates diurnal PA pattern for individual participant and 
the mean for each age subgroup. As can be seen in both Table 4 and Figure 9, the decrease in 
mean PA level from the 1st tertile to the 3rd tertile was observable in all 14 participants. Likewise, 
the decrease in PA from the 2nd tertile to the 3rd tertile was present in all but one participant 
(ED1013). 













ED001 182 234 188 126 54 
ED002 214 230 249 174 39 
ED003 215 293 197 160 68 
ED004 186 185 223 147 38 
ED005 251 322 281 151 89 
ED007 349 444 480 117 200 
ED008 303 362 355 185 100 
ED010 228 231 269 183 43 
ED011 371 404 453 248 107 
ED012 257 288 258 223 32 
ED013 287 316 252 293 33 
ED015 249 252 298 195 51 
ED017 174 219 188 119 51 
ED018 235 256 300 142 82 






Figure 8 - Mean 7-day activity count for the 1st tertile (7:08-12:22), 2nd tertile (12:23-17:37) and 3rd tertile (17:38-10:51).  
Each subject is identified by a specific symbol, and each subgroup by specific colour (red: younger-old subgroup; black: older-
old subgroup). Group means are represented by the solid red line and dashed black line, respectively.  
4.4.2 Sleep Parameters  
All sleep data were normally distributed. Descriptive results for extracted sleep parameters 
are presented for the full sample and both age subgroups in Table 5. 
Table 5 - Sleep Characteristics (Mean ± SD) Over the 7-Night Period  
Sleep Variables Full Sample Younger-old Older-old 
Time in bed (min) 483 ± 47 459 ± 45 503 ± 39 
SOL (min) 22 ± 17 34 ± 37 23 ± 21 
WASO (min) 65 ± 29 43 ± 14 81 ± 26 
TST (min) 383 ± 59 370 ± 63 386 ± 65 
Sleep Efficiency %           79 ± 9                 80 ± 9 76 ± 10 
Fragmentation index (%%) 45 ± 23                 30 ± 8 56 ± 25 




























Table 6 presents individual data for 7-night sleep parameters (TIB, SOL, WASO, TST, SE 
and FI). The two individuals with the highest SE are in blue, while those with the lowest SE are 
in red 
Table 6 - Individual Data (Mean ± SD) for 7 Night Sleep Parameters 
Subjects ID TIB (min) SOL (min) WASO (min) TST (min) SE% FI (%%) 
ED001 510 ± 64 8 ± 7 68 ± 17 416 ± 63 81 ± 4 42 ± 7 
ED002 557 ± 69 36 ± 29 74 ± 25 429 ± 79 77 ± 6 55 ± 15 
ED003 455 ± 64 30 ± 36 39 ± 11 377 ± 61 83 ± 8 24 ± 7 
ED004 514 ± 39 7 ± 5 51 ± 18 447 ± 31 87 ± 3 37 ± 7 
ED005 470 ± 86 58 ± 57 108 ± 47 300 ± 102 62 ± 10 92 ± 13 
ED007 504 ± 22 2 ± 1 22 ± 7 475 ± 27 94 ± 2 20 ± 7 
ED008 422 ± 72 23 ± 24 55 ± 24 332 ± 64 78 ± 3 23 ± 9 
ED010 429 ± 90 12 ± 19 113 ± 70 284 ± 41 68 ± 12 73 ± 20 
ED011 329 ± 53 23 ± 25 52 ± 16 312 ± 38 80 ± 5 40 ± 8 
ED012 528 ± 56  48 ± 34 104 ± 37 355 ± 41 68 ± 9 81 ± 14 
ED013 524 ± 52 8 ± 7 87 ± 11 423 ± 48 81 ± 2 50 ± 8 
ED015 501 ± 90 35 ± 31 59 ± 33 406 ± 75 81 ± 6 40 ± 16 
ED017 494 ± 51 6 ± 3 43 ± 17 436 ± 48 88 ± 3 17 ± 5 
ED018 457 ± 37 17 ± 17 36 ± 8 378 ± 28 83 ± 4 30 ± 14 
TIB: Time in Bed, SOL: Sleep Onset Latency, SE: Sleep Efficiency, WASO: wake after sleep onset, TST, total sleep time, FI: 
Fragmentation Index. Red: individuals with lowest SE, Blue: individuals with highest SE 
 
4.4.3 Correlation between Physical Activity and Sleep  
Table 7 contains correlations results between PA and sleep variables. There were no 
statistically significant correlations between mean 7-day PA or PA in each tertile of the day with 
any of the sleep parameters (SE, WASO, SOL, and FI). Correlation coefficients ranged from -
0.50 to 0.42. For daily PA, the strongest correlation observed was with TST (r = -0.23, p = 0.43), 
while PA in each tertile of the day as well as inter-tertile SD most strongly associated with 
WASO (r = -0.23, p = 0.43 for tertile 1; r = -0.29, p = 0.31 for tertile 2; r = 0.42, p = 0.13 for 
tertile 3; r = - 0.50, p = 0.07 for inter-tertile SD). Figure 10 depicts scatterplots of WASO over 





Table 7 - Correlation between PA variables (daily PA, PA in each tertile, and inter-tertile SD) 
with sleep parameters  
PA pattern Statistic SOL SE WASO TST FI 
Daily PA Pearson r 0.05 0.05 -0.13 -0.23 -0.05 
 
p 0.88 0.87 0.66 0.43 0.87 
1st Tertile Pearson r 0.06 0.11 -0.23 -0.16 -0.13 
 
p 0.85 0.70 0.43 0.59 0.66 
2nd Tertile  Pearson r -0.05 0.18 -0.29 -0.14 -0.15 
 
p 0.86 0.55 0.31 0.65 0.60 
3rd Tertile  Pearson r 0.20 -0.32 0.42 -0.31 0.32 
 
p 0.49 0.26 0.13 0.29 0.27 
Inter-tertile SD 
 
Spearman r -0.11 0.20 -0.50 -0.18 -0.49 
p 0.71 0.48 0.07 0.53 0.08 

























































Tables 8 and 9 display correlations results for the younger-old and older-old subgroups, 
respectively. While results were similar for both subgroups for certain associations (across the 3rd 
tertile for example), some evident disparities were noted between the two subgroups, particularly 
in the 2nd tertile of the day. 
 








Table 9- Association between PA variables and sleep parameters in Older-old subgroup 
 
Test SOL   SE WASO TST  FI 
Daily PA  Spearman's r 0.48 -0.48 0.48 -0.38 0.50 
 
p 0.23 0.23 0.23 0.35 0.21 
1st Tertile  Spearman's r 0.69 -0.67 0.67 -0.69 .71 
 
p 0.06 0.07 0.07 0.06 0.05 
2nd Tertile  Spearman's r  0.86 -0.95 0.95 -0.79 0.93 
 
p 0.01 0.00 0.00 0.02 0.00 
3rd Tertile Spearman's r 0.57 -0.57 0.69 -0.43 0.60 
 
p 0.14 0.14 0.06 0.29 0.12 
SOL: sleep onset latency, SE: sleep efficiency, WASO wake after sleep onset, TST: total sleep time & FI: 






Test SOL  SE  WASO  TST  FI  
Daily PA Spearman's r 0.37 -0.26 -0.09 0.20 -0.37 
 
p 0.47 0.62 0.87 0.70 0.49 
1st Tertile  Spearman's r -0.49 0.14 -0.49 -0.09 -0.66 
 
p 0.33 0.78 0.33 0.87 0.156 
2nd Tertile  Spearman's r -0.77 0.54 -0.37 0.20 -0.43 
 
p 0.07 0.27 0.49 0.70 0.40 
3rd Tertile  Spearman's r 0.60 -0.49 0.83 -0.60 0.71 
 
p 0.21 0.33 0.04 0.21 0.11 
SOL: sleep onset latency, SE: sleep efficiency, WASO wake after sleep onset, TST: total sleep time & FI: 





Figure 11 (panels A to D) illustrates scatterplots of daily PA and corresponding night sleep 
parameters (each data point) for the 7 monitoring days for each of the 14 participants (specific 
symbol per participant). No specific temporal association between daily PA and sleep parameters 
was identified.  
  
     
Figure 10 - Mean daily activity and corresponding night sleep parameters (each marker) for al 14 participants 
(specific symbol per participant). TST: total sleep time, SE: sleep efficiency, WASO: wake after sleep onset, FI: 


















































4.5 Discussion  
4.5.1 Diurnal Physical Activity Patterns  
The first objective of the study was to describe diurnal patterns of PA in COPD patients. It 
was hypothesised that PA levels would decrease throughout the day. Our findings support this 
hypothesis, but more precisely suggest that mean PA levels drop particularly in the evening. This 
observation was highly homogeneous across our sample, with evening PA being less than 
morning PA in 14/14 patients and less than afternoon PA in 13/14 patients. Our study 
participants, who were conveniently sampled, unexpectedly formed two distinct age subgroups, 
which were characterized a posteriori as younger-old (57-67 years, mean = 64 years) and older-
old (74-79 years, mean = 77 years) patients.  Although younger-old patients displayed higher PA 
levels in the morning and afternoon compared to their older-old counterparts, both subgroups fell 
to similar low levels of PA in the evening (Figure 9). 
In the literature, studies examining diurnal PA patterns are scarce, both in the general 
population and in COPD patients. One study conducted in an elderly healthy population (mean 
age = 73 ± 3 years) showed that participants were mostly active from 6 to17h and that activity 
levels then decreased in the evening (116). In COPD patients, to our knowledge, only one study 
by Tabak et al. (105) evaluated diurnal patterns of PA. They too reported a significant decrease 
in activity levels from the morning (8-13h) and afternoon (13-13h) to the evening (17-20h) in 
unemployed COPD patients (n = 32). They also observed the same pattern, but not statistically 
significant, in employed COPD patients (n = 7) and unemployed healthy controls (n = 10). 
Conversely, in employed healthy controls (n = 11), they reported an “A-shape” pattern, where 
PA levels peaked in the afternoon, but were similar between morning and evening (105). Of 
note, the healthy control group in Tabak et al.’s study (105) was significantly younger than the 
COPD group. Overall, it is therefore difficult at this point in time to delineate the role of COPD 
per se versus factors associated with the disease (age, employment, etc.) on diurnal PA patterns. 
The suggested link between employment status and PA levels/patterns warrants replication in 




 As part of our first objective, we also explored PA patterns according to three different 
data handling approaches: an arbitrary, a mealtime, and an equal tertiles splitting approach. The 
arbitrary split, based on prior studies (105), considered only 12 hours of the day, from 8:00 to 
20:00, while the other two methods considered the full window of hours between wake time and 
bedtime. Regardless of the splitting approach, PA levels decreased significantly in the evening, 
but the extent of the decrease, which was similar between mealtime and equal tertiles splits, was 
less with the arbitrary approach. Given that diurnal PA patterns have not been examined much in 
any population, there are no guidelines as to which approach should be favoured. Studies in other 
chronic conditions (chronic lower back pain (112) and chronic fatigue syndrome (179)) have 
used arbitrary approaches (e.g., 8:00-12:00, 12:00-18:00 and 18:00-22:00), similar to Tabak and 
colleagues (105) in their study in COPD (8:00-13:00, 13:00-17:00 and 17:00-20:00).  
An important issue with the arbitrary approach is that valuable data are missed in the 
morning (between actual wake time and the arbitrarily set day onset time, e.g. 8:00) and in the 
evening (between day offset time and actual bedtime). Since PA levels were reported in average 
counts per minute in the present study, decreasing the monitoring window (denominator) with 
the arbitrary approach resulted in an increased count for morning and evening PA (Table 3). 
Another issue with this approach is that splitting the day arbitrarily may not reflect patients’ 
daily routines. Food intake, for example, is related to individual habits and social norms (180). 
Empirically setting day onset and offset with actual wake time and bedtime, and splitting the day 
according to self-reported meal times allows for a more ecological and individualized data 
extraction. However, it requires much more data handling and the completion of daily journals 
for meal times. The equal tertiles approach does not decrease data handling requirements, but 
removes the need for daily journals, which would be a valuable feature for large population 
studies. Another advantage of the equal tertiles approach is that each portion of the day contains 
the exact same number of hours. According to our findings, it results in similar morning, 
afternoon, and evening PA counts as the mealtime approach, thus potentially offering a 






4.5.2 Sleep Quality  
The second objective of the study was to describe sleep quality in COPD patients, with the 
hypothesis that actigraphy-assessed sleep parameters would suggest poor sleep quality 
(particularly a reduced SE).  Our study participants had, on average, a SE of 79 ± 9%, about one 
hour (65 ± 29 minutes) of WASO, over six hours (383 ± 59 minutes) of TST, and 22 ± 17 
minutes of SOL. These findings are somewhat discrepant from earlier results from Nunes et al. 
(162) comparing actigraphy-measured sleep in COPD patient (n = 26) versus age-matched 
healthy controls (n = 15). In their study, COPD patients were reported to have a SE of 73%, 96 
minutes of WASO, less than five hours (280 minutes) of TST, and 40 minutes of SOL; the 
corresponding numbers for their age-matched healthy controls were a SE of 87%, 49 minutes of 
WASO, six hours (360 minutes) of TST, and 11 minutes of SOL. Thus, patients who participated 
in the present study had relatively preserved sleep quality parameters compared to those who 
completed Nunes et al.’s (162) investigation. This is perhaps not surprising since our participants 
had predominantly moderate COPD, while theirs included severe and very severe patients. 
Nevertheless, the mean values obtained for SE, WASO, and SOL in the present study suggest 
some degree of sleep disturbance in a sample of patients with mostly moderate COPD, 
resembling or even surpassing what has been documented with actigraphy in older adults with 
insomnia (167).  
Studies using polysomnography (PSG) to characterize sleep in COPD patients have also 
documented decreased SE (132, 181, 182). Hynninen et al. (182) reported impaired SE (< 85 %) 
in 57.5 % of the COPD patients who took part in their study. Similarly, Valipour et al. (132) 
documented significantly lower SE in COPD patients compared to healthy controls (SE: 75 ± 
13% and 82 ± 11% for COPD and healthy controls, respectively).  The causes of disturbed sleep 
in COPD patients are not yet fully understood, but seem to stem from a complex and 
multifactorial process, possibly due to one or more of the following factors: hypoxemia, 
hypercapnia, physiological changes associated with sleep, inflammation, COPD medications, 
and/or nicotine use (135). Furthermore, COPD is commonly diagnosed later in life, in middle- or 
old-age adults, and in individuals who are mostly long-term smokers and who often suffer from 
comorbidities associated with smoking and /or old age. In the general population, it is well 




this is also likely true for COPD patients. In the present study, the older-old subgroup showed 
lower SE and higher WASO and FI compared to the younger-old subgroup, which is typical of 
the aging effect on sleep. In return, the older-old subgroup had lower SOL and higher TST 
compared to the younger-old subgroup. Sex may have influenced this later observation since the 
older-old subgroup was entirely composed of males, while the younger-old subgroup consisted 
predominantly (83%) of females, and sex differences in sleep quality in favour of males have 
been previously noted (183). Additional studies with larger sample sizes and consideration of age 
and sex will be needed to further characterize sleep quality in COPD patients in an ecological 
setting.  
4.5.3 Correlation between Physical Activity and Sleep  
The third objective of our study was to explore the association between daily PA and sleep 
quality parameters in COPD patients, with the hypothesis that there would be a positive 
relationship between these two health behaviours. Our findings generally suggest very weak to 
weak correlations between mean daily PA counts and sleep quality parameters. When PA was 
broken down into tertiles of the day, and when inter-tertile SD (a measure of within-day 
variability in PA) was considered, stronger correlation coefficients with sleep parameters were 
observed. Of the sleep parameters assessed in the present study, WASO showed the strongest 
associations with PA in each tertile of the day and inter-tertile SD. Furthermore, within-subject 
examination of temporal (day with corresponding night) associations between PA and sleep 
parameters discerned no identifiable pattern.  
Very few studies have examined the relationship between PA and sleep using objective 
measurements of both variables. In COPD patients, to our knowledge, this is the first report of 
any type of association between habitual PA and sleep parameters. Our results regarding the 
weak correlations between mean daily PA and sleep parameters are in line with findings from 
Lambiase et al. (148), which documented no association between objectively measured average 
weakly PA and average weakly sleep parameters in older women. Additionally, another study by 
Youngstdt et al. (154) reported no association between daily PA and sleep parameters in healthy 
normal sleepers. Physical activity has been shown to be associated with sleep quality particularly 




sleep; this may explain the weak associations observed between PA and sleep parameters. Future 
trials investigating this relationship may want to target COPD patients with documented sleep 
disturbances. There are no prior studies which we know of that have examined the association 
between sleep parameters and PA in different parts of the day. Based on the present findings, 
future studies should consider breaking down daily PA into periods of the day and include a 
measure of within-day PA variability (e.g., inter-tertile SD) to examine the relationship with 
sleep. 
Of note, our two age subgroups showed quite different patterns of associations between PA 
and sleep, particularly for the 2nd tertile of the day. Given the size of these subgroups (8 and 6), 
inferences should not be made based on these findings. However, they highlight the importance 
of considering age (and sex, as mentioned above) in future studies looking at PA and sleep, 
otherwise important associations may be overlooked. Although the relationship between PA and 
sleep across different age groups has not been precisely examined, it is well documented that age 
greatly influences both PA (184, 185) and sleep (178).   
4.5.4 Clinical Implication 
In the present study, a tri-axial accelerometer was used to describe diurnal patterns of PA 
and standard sleep quality parameters in COPD patient. Our results add to those of Tabak and 
colleagues (105) to provide a better understanding of within-day PA behaviour in COPD and 
may, in the long term, offer valuable insight for interventions targeting PA. Further, we 
compared three different data handling approaches for the evaluation of PA patterns: an 
arbitrary, mealtime, and equal tertiles approach. Our findings suggest that the equal tertiles 
approach may present a valuable option, particularly for large trials, since it seems to lead to 
similar counts as the ecological mealtime approach, but does not require the daily completion of 
a journal. For applications in large population studies, computer-programming algorithms should 
be considered for the determination of wake times and bedtimes and for the equal tertiles split, as 
it would reduce risk of errors and simplify data handling. Moreover, our results somewhat 
support previous findings of a reduced sleep quality in COPD patients, but highlight the need for 
additional research on the characterization of sleep quality in COPD patients in an ecological 




parameters in COPD patients. Our findings of an inverse association between within-day PA 
variability and parameters of “poor” sleep quality (WASO and FI) challenges the current 
recommendations to balance energy expenditure throughout the day (because as within-day PA 
variability increased, parameters of sleep fragmentation decreased). The results obtained may be 
helpful in generating hypotheses about this likely complex relationship.  
4.5.5 Limitations 
There are several limitations that should be taken into consideration in the interpretation of 
the present findings and for future studies on the subject. First, the sampling approach 
(convenience sampling) may have introduced a selection bias, thereby affecting the study’s both 
internal and external validity. Likewise, the lack of a control group limits the internal validity. 
Even though levels of PA have been monitored objectively in COPD populations in previous 
studies, due to differences in the devices used to measure PA across studies, comparisons to prior 
findings is limited. Furthermore, this is only the second study on diurnal PA patterns in COPD 
patients, and the inclusion of a control group would have provided a better understanding of the 
influence of COPD per se on PA patterns within a day. Lastly, the small sample size limits the 
generalizability of the findings. Also due to the small sample size, it was not reasonably possible 
to control for potential covariates that may influence both PA and sleep (e.g., age, sex, BMI, etc).  
4.5.6 Future Directions  
Larger studies with age- and sex- matched healthy control groups will be needed to 
confirm, clarify, and/or further test our findings and put them into perspective with the general 
older adult population. A larger sample will allow for advanced statistical analyses with the 
ability to control for covariates if needed. It may also provide more variability in PA and sleep 
parameters, which would help detect patterns of association, if such patterns are present. 
Furthermore, having information on participants’ employment status or, ideally, including 
employed and unemployed participants may be of importance in understanding diurnal PA 
patterns of COPD patients. Lastly, further exploring within-subject temporal associations 
between physical activity and sleep as well as examining their interactive effects on disease 





In summary, result from this study support prior findings that PA levels decrease 
significantly in the evening compared to both morning and afternoon in COPD patients. They 
further suggest that the data handling approach used to evaluate diurnal PA patterns may affect 
the extent of the decrease observed. The equal tertiles handling approach may offer a valuable 
compromise between the common arbitrary approach and the more ecological mealtime 
approach. Based on the mean values obtained for SE, WASO, and SOL in the present study, 
some degree of sleep disturbances may be present, even in patients with moderate COPD. The 
association between PA and sleep quality parameters appears to be generally weak in this subset 
of patients compared to what was previously shown in “healthy” poor sleepers, but the PA-sleep 





5.0 References  
1. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 
2012;379(9823):1341-51. 
2. Global Strategy For The Diagnosis, Management and Prevention Of Chronic Obstructive 
Lung Disease. Global Initiative for Chronic Obstructive Lung Disease Inc. 2013:1-99. 
3. Celli BR, MacNee W, Agusti A, Anzueto A, Berg B, Buist AS, et al. Standards for the 
diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. 
European Respiratory Journal. 2004;23(6):932-46. 
4. American Thoracic Society. What constitutes an adverse health effect of air pollution? 
Official statement of the American Thoracic Society. Am J Respir Crit Care Med. 2000;161(2 
Pt 1):665-73. 
5. Gea J, Agusti A, Roca J. Pathophysiology of muscle dysfunction in COPD. J Appl Physiol. 
2013;114(9):1222-34. 
6. DiBonaventura M, Paulose-Ram R, Su J, McDonald M, Zou KH, Wagner JS, et al. The 
burden of chronic obstructive pulmonary disease among employed adults. Int J Chron 
Obstruct Pulmon Dis. 2012;7:211-9. 
7. Petrovic M, Reiter M, Zipko H, Pohl W, Wanke T. Effects of inspiratory muscle training on 
dynamic hyperinflation in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:797-
805. 
8. society AT. Standards For Diagnosis and Managment of  patietns with COPD. American 
Thoracic society. 2004:1-222. 
9. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, et al. 





10. Penedo FJ, Dahn JR. Exercise and well-being: a review of mental and physical health benefits 
associated with physical activity. Current opinion in psychiatry. 2005;18(2):189-93. 
11. O'Donnell DE, Hernandez P, Kaplan A, Aaron S, Bourbeau J, Marciniuk D, et al. Canadian 
Thoracic Society recommendations for management of chronic obstructive pulmonary disease 
- 2008 update - highlights for primary care. Can Respir J. 2008;15 Suppl A:1A-8A. 
12. Najafzadeh M, Marra CA, Lynd LD, Sadatsafavi M, FitzGerald JM, McManus B, et al. Future 
impact of various interventions on the burden of COPD in Canada: a dynamic population 
model. PLoS One. 2012;7(10):e46746. 
13. Gershon AS, Wang C, Wilton AS, Raut R, To T. Trends in chronic obstructive pulmonary 
disease prevalence, incidence, and mortality in ontario, Canada, 1996 to 2007: a population-
based study. Arch Intern Med. 2010;170(6):560-5. 
14. Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, Carrozzi L. Definition, epidemiology and 
natural history of COPD. Eur Respir J. 2007;30(5):993-1013. 
15. Raherison C, Girodet PO. Epidemiology of COPD. Eur Respir Rev. 2009;18(114):213-21. 
16. Wang J, Urbanowicz RA, Tighe PJ, Todd I, Corne JM, Fairclough LC. Differential activation 
of killer cells in the circulation and the lung: a study of current smoking status and chronic 
obstructive pulmonary disease (COPD). PLoS One. 2013;8(3):e58556. 
17. Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive 
pulmonary disease. The Lancet. 2015;385(9971):899-909. 
18. Saetta GTRZM. Pathogenesis and Pathology of COPD. ￼Respiration 
. 2001;68:117–28. 
19. Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest. 
2012;122(8):2749-55. 
20. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a 
summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-46. 
21. Calverley PM, Koulouris NG. Flow limitation and dynamic hyperinflation: key concepts in 




22. Lamb D, McLean A, Gillooly M, Warren PM, Gould GA, MacNee W. Relation between 
distal airspace size, bronchiolar attachments, and lung function. Thorax. 1993;48(10):1012-7. 
23. O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive 
pulmonary disease. Proc Am Thorac Soc. 2006;3(2):180-4. 
24. Pepe PE, Marini JJ. Occult positive end-expiratory pressure in mechanically ventilated 
patients with airflow obstruction: the auto-PEEP effect. Am Rev Respir Dis. 
1982;126(1):166-70. 
25. Gea J, Orozco-Levi M, Barreiro E, Ferrer A, Broquetas J. Structural and functional changes in 
the skeletal muscles of COPD patients: the "compartments" theory. Monaldi Arch Chest Dis. 
2001;56(3):214-24. 
26. Gea J, Agusti A, Roca J. Pathophysiology of muscle dysfunction in COPD. J Appl Physiol 
(1985). 2013;114(9):1222-34. 
27. Donaire-Gonzalez D, Gimeno-Santos E, Balcells E, Rodriguez DA, Farrero E, de Batlle J, et 
al. Physical activity in COPD patients: patterns and bouts. Eur Respir J. 2013;42(4):993-1002. 
28. Gea J, Casadevall C, Pascual S, Orozco-Levi M, Barreiro E. Respiratory diseases and muscle 
dysfunction. Expert Rev Respir Med. 2012;6(1):75-90. 
29. Epstein SK. An overview of respiratory muscle function. Clin Chest Med. 1994;15(4):619-39. 
30. Shiota S, Okada T, Naitoh H, Ochi R, Fukuchi Y. Hypoxia and hypercapnia affect contractile 
and histological properties of rat diaphragm and hind limb muscles. Pathophysiology. 
2004;11(1):23-30. 
31. Barreiro E, Peinado VI, Galdiz JB, Ferrer E, Marin-Corral J, Sanchez F, et al. Cigarette 
smoke-induced oxidative stress: A role in chronic obstructive pulmonary disease skeletal 
muscle dysfunction. Am J Respir Crit Care Med. 2010;182(4):477-88. 
32. Decramer M, de Bock V, Dom R. Functional and histologic picture of steroid-induced 





33. Hopkinson NS, Tennant RC, Dayer MJ, Swallow EB, Hansel TT, Moxham J, et al. A 
prospective study of decline in fat free mass and skeletal muscle strength in chronic 
obstructive pulmonary disease. Respir Res. 2007;8:25. 
34. Van't Hul A, Harlaar J, Gosselink R, Hollander P, Postmus P, Kwakkel G. Quadriceps muscle 
endurance in patients with chronic obstructive pulmonary disease. Muscle Nerve. 
2004;29(2):267-74. 
35. Seymour JM, Spruit MA, Hopkinson NS, Natanek SA, Man WD, Jackson A, et al. The 
prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur 
Respir J. 2010;36(1):81-8. 
36. Pepin V, Saey D, Laviolette L, Maltais F. Exercise capacity in chronic obstructive pulmonary 
disease: mechanisms of limitation. COPD. 2007;4(3):195-204. 
37. Martinez FJ, Foster G, Curtis JL, Criner G, Weinmann G, Fishman A, et al. Predictors of 
mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care 
Med. 2006;173(12):1326-34. 
38. Palange P, Wagner PD. "The skeletal muscle in chronic respiratory diseases", summary of the 
ERS research seminar in Rome, Italy, February 11-12 1999. Eur Respir J. 2000;15(4):807-15. 
39. O'Donnell DE, Bertley JC, Chau LK, Webb KA. Qualitative aspects of exertional 
breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit 
Care Med. 1997;155(1):109-15. 
40. Killian KJ, Leblanc P, Martin DH, Summers E, Jones NL, Campbell EJ. Exercise capacity 
and ventilatory, circulatory, and symptom limitation in patients with chronic airflow 
limitation. Am Rev Respir Dis. 1992;146(4):935-40. 
41. Pepin V, Laviolette L, Saey D, Maltais F. Synergetic interactions between rehabilitation and 
pharmacotherapy in COPD. Clin Invest Med. 2006;29(3):170-7. 
42. Pepin V, Saey D, Whittom F, LeBlanc P, Maltais F. Walking versus cycling: sensitivity to 





43. Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC, Richter K, et al. 
Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium 
in patients with COPD. Chest. 2005;128(3):1168-78. 
44. Negewo NA, McDonald VM, Gibson PG. Comorbidity in chronic obstructive pulmonary 
disease. Respir Investig. 2015;53(6):249-58. 
45. Cavailles A, Brinchault-Rabin G, Dixmier A, Goupil F, Gut-Gobert C, Marchand-Adam S, et 
al. Comorbidities of COPD. Eur Respir Rev. 2013;22(130):454-75. 
46. Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, van Empel VP, Bruijnzeel PL, et al. 
Clusters of comorbidities based on validated objective measurements and systemic 
inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care 
Med. 2013;187(7):728-35. 
47. Schnell K, Weiss CO, Lee T, Krishnan JA, Leff B, Wolff JL, et al. The prevalence of 
clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-
sectional study using data from NHANES 1999-2008. BMC Pulm Med. 2012;12:26. 
48. Global recommendations on physical activity for health. World Health Organization. 2010:1-
60. 
49. COPD Guidlines: What Are the Signs and Symptoms of COPD? American Thoracic society. 
2015. 
50. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation 
of spirometry. Eur Respir J. 2005;26(2):319-38. 
51. Canadian Lung Association - fighting lung disease for over 100 years. Canadian Lung 
Association [Internet]. 2012 [cited 2013 07-05]. Available from: http://www.lung.ca/diseases-
maladies/copd-mpoc_e.php. 
52. COPD Guidlines: What Is an Exacerbation? American Thoracic society. 2015. 
53. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility 





54. CTS COPD Guidelines [Internet]. 2010 [cited 2013/12/07]. Available from: 
http://bcrt.ca/tag/canadian-thoracic-society/. 
55. Manini TM, Everhart JE, Patel KV, Schoeller DA, Colbert LH, Visser M, et al. Daily activity 
energy expenditure and mortality among older adults. JAMA. 2006;296(2):171-9. 
56. Caspersen CJ, Pereira MA, Curran KM. Changes in physical activity patterns in the United 
States, by sex and cross-sectional age. Med Sci Sports Exerc. 2000;32(9):1601-9. 
57. Vorrink SN, Kort HS, Troosters T, Lammers JW. Level of daily physical activity in 
individuals with COPD compared with healthy controls. Respir Res. 2011;12:33. 
58. Katajisto M, Kupiainen H, Rantanen P, Lindqvist A, Kilpelainen M, Tikkanen H, et al. 
Physical inactivity in COPD and increased patient perception of dyspnea. Int J Chron 
Obstruct Pulmon Dis. 2012;7:743-55. 
59. Waschki B, Spruit MA, Watz H, Albert PS, Shrikrishna D, Groenen M, et al. Physical activity 
monitoring in COPD: compliance and associations with clinical characteristics in a 
multicenter study. Respir Med. 2012;106(4):522-30. 
60. Katajisto M, Koskela J, Lindqvist A, Kilpelainen M, Laitinen T. Physical activity in COPD 
patients decreases short-acting bronchodilator use and the number of exacerbations. Respir 
Med. 2015;109(10):1320-5. 
61. Garcia-Aymerich J, Serra I, Gomez FP, Farrero E, Balcells E, Rodriguez DA, et al. Physical 
activity and clinical and functional status in COPD. Chest. 2009;136(1):62-70. 
62. Donaire-Gonzalez D, Gimeno-Santos E, Balcells E, de Batlle J, Ramon MA, Rodriguez E, et 
al. Benefits of physical activity on COPD hospitalisation depend on intensity. Eur Respir J. 
2015;46(5):1281-9. 
63. Nguyen HQ, Chu L, Amy Liu IL, Lee JS, Suh D, Korotzer B, et al. Associations between 
Physical Activity and 30-Day Readmission Risk in Chronic Obstructive Pulmonary Disease. 
Ann Am Thorac Soc. 2014;11(5):695-705. 
64. Valenza MC, Torres-Sanchez I, Cabrera-Martos I, Rodriguez-Torres J, Gonzalez-Jimenez E, 
Munoz-Casaubon T. Physical Activity as a Predictor of Absence of Frailty in Subjects With 




65. Durr S, Zogg S, Miedinger D, Steveling EH, Maier S, Leuppi JD. Daily Physical Activity, 
Functional Capacity and Quality of Life in Patients with COPD. COPD. 2014. 
66. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM. Regular physical activity 
modifies smoking-related lung function decline and reduces risk of chronic obstructive 
pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med. 
2007;175(5):458-63. 
67. Hopkinson NS, Polkey MI. Does physical inactivity cause chronic obstructive pulmonary 
disease? Clin Sci (Lond). 2010;118(9):565-72. 
68. Jakes RW, Day NE, Patel B, Khaw KT, Oakes S, Luben R, et al. Physical inactivity is 
associated with lower forced expiratory volume in 1 second : European Prospective 
Investigation into Cancer-Norfolk Prospective Population Study. Am J Epidemiol. 
2002;156(2):139-47. 
69. Pelkonen M, Notkola IL, Lakka T, Tukiainen HO, Kivinen P, Nissinen A. Delaying decline in 
pulmonary function with physical activity: a 25-year follow-up. Am J Respir Crit Care Med. 
2003;168(4):494-9. 
70. Cheng YJ, Macera CA, Addy CL, Sy FS, Wieland D, Blair SN. Effects of physical activity on 
exercise tests and respiratory function. Br J Sports Med. 2003;37(6):521-8. 
71. Canoy D, Pekkanen J, Elliott P, Pouta A, Laitinen J, Hartikainen AL, et al. Early growth and 
adult respiratory function in men and women followed from the fetal period to adulthood. 
Thorax. 2007;62(5):396-402. 
72. Hartman JE, Boezen HM, Zuidema MJ, de Greef MH, Ten Hacken NH. Physical activity 
recommendations in patients with chronic obstructive pulmonary disease. Respiration. 
2014;88(2):92-100. 
73. Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King AC, et al. Physical activity 
and public health in older adults: recommendation from the American College of Sports 
Medicine and the American Heart Association. Med Sci Sports Exerc. 2007;39(8):1435-45. 
74. Canadian Physical Activity Guidlines, Canadian sedentary Behavior Guidlines. Canadian 




75. Harman D. The free radical theory of aging. Antioxid Redox Signal. 2003;5(5):557-61. 
76. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al. American 
College of Sports Medicine position stand. Quantity and quality of exercise for developing 
and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently 
healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc. 2011;43(7):1334-59. 
77. CARL J.CASPERSEN KEP, GREGORY M. CHRISTENSON, . Physical Activity, Exercise, 
and Physical Fitness: Definitions and Distinctions for Health-Related Research. Public Health 
reports. 1985;100(2):126-31. 
78. Matthews CE, Jurj AL, Shu XO, Li HL, Yang G, Li Q, et al. Influence of exercise, walking, 
cycling, and overall nonexercise physical activity on mortality in Chinese women. Am J 
Epidemiol. 2007;165(12):1343-50. 
79. Benzo R. Activity monitoring in chronic obstructive pulmonary disease. J Cardiopulm 
Rehabil Prev. 2009;29(6):341-7. 
80. Patel SA, Benzo RP, Slivka WA, Sciurba FC. Activity monitoring and energy expenditure in 
COPD patients: a validation study. COPD. 2007;4(2):107-12. 
81. Gosker HR, Lencer NH, Franssen FM, van der Vusse GJ, Wouters EF, Schols AM. Striking 
similarities in systemic factors contributing to decreased exercise capacity in patients with 
severe chronic heart failure or COPD. Chest. 2003;123(5):1416-24. 
82. Schutz Y, Weinsier RL, Hunter GR. Assessment of free-living physical activity in humans: an 
overview of currently available and proposed new measures. Obes Res. 2001;9(6):368-79. 
83. Garcia-Aymerich J, Farrero E, Felez MA, Izquierdo J, Marrades RM, Anto JM, et al. Risk 
factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax. 
2003;58(2):100-5. 
84. De Cocker KA, De Bourdeaudhuij IM, Cardon GM. What do pedometer counts represent? A 
comparison between pedometer data and data from four different questionnaires. Public 
Health Nutr. 2009;12(1):74-81. 
85. Le Masurier GC, Tudor-Locke C. Comparison of pedometer and accelerometer accuracy 




86. Danilack VA, Okunbor O, Richardson CR, Teylan M, Moy ML. Performance of a pedometer 
to measure physical activity in a U.S. cohort with chronic obstructive pulmonary disease. J 
Rehabil Res Dev. 2015;52(3):333-42. 
87. Bossenbroek L, de Greef MH, Wempe JB, Krijnen WP, Ten Hacken NH. Daily physical 
activity in patients with chronic obstructive pulmonary disease: a systematic review. COPD. 
2011;8(4):306-19. 
88. Van Remoortel H, Raste Y, Louvaris Z, Giavedoni S, Burtin C, Langer D, et al. Validity of 
six activity monitors in chronic obstructive pulmonary disease: a comparison with indirect 
calorimetry. PLoS One. 2012;7(6):e39198. 
89. Gimeno-Santos E, Raste Y, Demeyer H, Louvaris Z, de Jong C, Rabinovich RA, et al. The 
PROactive instruments to measure physical activity in patients with chronic obstructive 
pulmonary disease. Eur Respir J. 2015;46(4):988-1000. 
90. Schonhofer B, Ardes P, Geibel M, Kohler D, Jones PW. Evaluation of a movement detector 
to measure daily activity in patients with chronic lung disease. Eur Respir J. 
1997;10(12):2814-9. 
91. Walker PP, Burnett A, Flavahan PW, Calverley PM. Lower limb activity and its determinants 
in COPD. Thorax. 2008;63(8):683-9. 
92. Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Eur 
Respir J. 2009;33(2):262-72. 
93. Watz H, Waschki B, Boehme C, Claussen M, Meyer T, Magnussen H. Extrapulmonary 
effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. 
Am J Respir Crit Care Med. 2008;177(7):743-51. 
94. Minakata Y, Sugino A, Kanda M, Ichikawa T, Akamatsu K, Koarai A, et al. Reduced level of 
physical activity in Japanese patients with chronic obstructive pulmonary disease. Respir 
Investig. 2014;52(1):41-8. 
95. Van Remoortel H, Hornikx M, Demeyer H, Langer D, Burtin C, Decramer M, et al. Daily 




96. Hernandes NA, Teixeira Dde C, Probst VS, Brunetto AF, Ramos EM, Pitta F. Profile of the 
level of physical activity in the daily lives of patients with COPD in Brazil. J Bras Pneumol. 
2009;35(10):949-56. 
97. Troosters T, Sciurba F, Battaglia S, Langer D, Valluri SR, Martino L, et al. Physical inactivity 
in patients with COPD, a controlled multi-center pilot-study. Respir Med. 2010;104(7):1005-
11. 
98. Park SK, Richardson CR, Holleman RG, Larson JL. Physical activity in people with COPD, 
using the National Health and Nutrition Evaluation Survey dataset (2003-2006). Heart Lung. 
2013;42(4):235-40. 
99. Pitta F, Troosters T, Spruit MA, Decramer M, Gosselink R. Activity monitoring for 
assessment of physical activities in daily life in patients with chronic obstructive pulmonary 
disease. Arch Phys Med Rehabil. 2005;86(10):1979-85. 
100. Singh S, Morgan MD. Activity monitors can detect brisk walking in patients with chronic 
obstructive pulmonary disease. J Cardiopulm Rehabil. 2001;21(3):143-8. 
101. Coronado M, Janssens JP, de Muralt B, Terrier P, Schutz Y, Fitting JW. Walking activity 
measured by accelerometry during respiratory rehabilitation. J Cardiopulm Rehabil. 
2003;23(5):357-64. 
102. Pitta F, Takaki MY, Oliveira NH, Sant'anna TJ, Fontana AD, Kovelis D, et al. Relationship 
between pulmonary function and physical activity in daily life in patients with COPD. Respir 
Med. 2008;102(8):1203-7. 
103. Steele GB BB, Kevin Cain, Catherine Warms, Jeff COppersmith, JoEllen Howard. Bodies in 
motion:Motitoing daily activity and exercise with motion sensors in people wiht chronic 
pulmonary disease. Journal of Rehabilitation Research adn Development. 2003;40(5):45-58. 
104. Jehn M, Schindler C, Meyer A, Tamm M, Koehler F, Witt C, et al. Associations of daily 
walking activity with biomarkers related to cardiac distress in patients with chronic 
obstructive pulmonary disease. Respiration. 2013;85(3):195-202. 
105. Tabak M, Vollenbroek-Hutten MM, van der Valk PD, van der Palen J, Tonis TM, Hermens 
HJ. Telemonitoring of Daily Activity and Symptom Behavior in Patients with COPD. Int J 




106. Sandland CJ, Singh SJ, Curcio A, Jones PM, Morgan MD. A profile of daily activity in 
chronic obstructive pulmonary disease. J Cardiopulm Rehabil. 2005;25(3):181-3. 
107. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of 
physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit 
Care Med. 2005;171(9):972-7. 
108. Jehn M, Schmidt-Trucksass A, Meyer A, Schindler C, Tamm M, Stolz D. Association of daily 
physical activity volume and intensity with COPD severity. Respir Med. 2011;105(12):1846-
52. 
109. Waschki B, Kirsten AM, Holz O, Mueller KC, Schaper M, Sack AL, et al. Disease 
Progression and Changes in Physical Activity in Patients with Chronic Obstructive Pulmonary 
Disease. Am J Respir Crit Care Med. 2015;192(3):295-306. 
110. Donaire-Gonzalez D, Gimeno-Santos E, Balcells E, Rodriguez DA, Farrero E, Batlle JD, et 
al. Physical activity in COPD patients: patterns and bouts. Eur Respir J. 2012. 
111. Steele GB LH, Basia Belza, Scott Ferris,  S. Lakshminaryan, David M. Buchner. Quantitating 
Physical Activity in COPD Using a Triaxial Accelerometer. CHEST 2000;117(5):1359-67. 
112. van Weering MG, Vollenbroek-Hutten MM, Tonis TM, Hermens HJ. Daily physical activities 
in chronic lower back pain patients assessed with accelerometry. Eur J Pain. 2009;13(6):649-
54. 
113. Fregonezi G, Resqueti VR, Cury JL, Paulin E, Brunetto AF. Diurnal variations in the 
parameters of pulmonary function and respiratory muscle strength in patients with COPD. J 
Bras Pneumol. 2012;38(2):257-63. 
114. Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, et al. 
Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur 
Respir J. 2011;37(2):264-72. 
115. Chan-Thim E, Dumont M, Moullec G, Rizk AK, Wardini R, Trutschnigg B, et al. Clinical 
impact of time of day on acute exercise response in COPD. COPD. 2014;11(2):204-11. 
116. Shirota A, Tamaki M, Hayashi M, Hori T. Effects of daytime activity on nocturnal sleep in 




117. Matthews CE, Ainsworth BE, Thompson RW, Bassett DR, Jr. Sources of variance in daily 
physical activity levels as measured by an accelerometer. Med Sci Sports Exerc. 
2002;34(8):1376-81. 
118. Crinion SJ, McNicholas WT. Sleep-related disorders in chronic obstructive pulmonary 
disease. Expert Rev Respir Med. 2014;8(1):79-88. 
119. Lan CC, Huang HC, Yang MC, Lee CH, Huang CY, Wu YK. Pulmonary rehabilitation 
improves subjective sleep quality in COPD. Respir Care. 2014;59(10):1569-76. 
120. Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Quantity and quality of sleep and incidence 
of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2010;33(2):414-20. 
121. Nunes DM, Mota RM, de Pontes Neto OL, Pereira ED, de Bruin VM, de Bruin PF. Impaired 
sleep reduces quality of life in chronic obstructive pulmonary disease. Lung. 
2009;187(3):159-63. 
122. Narang I, Manlhiot C, Davies-Shaw J, Gibson D, Chahal N, Stearne K, et al. Sleep 
disturbance and cardiovascular risk in adolescents. CMAJ. 2012;184(17):E913-20. 
123. Omachi TA, Blanc PD, Claman DM, Chen H, Yelin EH, Julian L, et al. Disturbed sleep 
among COPD patients is longitudinally associated with mortality and adverse COPD 
outcomes. Sleep Med. 2012;13(5):476-83. 
124. McNicholasI WT. Impact of Sleep in COPD. CHEST 2000;117(2). 
125. McNicholas WT, Verbraecken J, Marin JM. Sleep disorders in COPD: the forgotten 
dimension. Eur Respir Rev. 2013;22(129):365-75. 
126. O'Donnell D, Silva EJ, Munch M, Ronda JM, Wang W, Duffy JF. Comparison of subjective 
and objective assessments of sleep in healthy older subjects without sleep complaints. J Sleep 
Res. 2009;18(2):254-63. 
127. Sateia MJ, Doghramji K, Hauri PJ, Morin CM. Evaluation of chronic insomnia. An American 
Academy of Sleep Medicine review. Sleep. 2000;23(2):243-308. 
128. Sivertsen B, Omvik S, Havik OE, Pallesen S, Bjorvatn B, Nielsen GH, et al. A comparison of 





129. Marino M, Li Y, Rueschman MN, Winkelman JW, Ellenbogen JM, Solet JM, et al. 
Measuring sleep: accuracy, sensitivity, and specificity of wrist actigraphy compared to 
polysomnography. Sleep. 2013;36(11):1747-55. 
130. Ancoli-Israel S, Cole R, Alessi C, Chambers M, Moorcroft W, Pollak CP. The role of 
actigraphy in the study of sleep and circadian rhythms. Sleep. 2003;26(3):342-92. 
131. Budhiraja R, Parthasarathy S, Budhiraja P, Habib MP, Wendel C, Quan SF. Insomnia in 
patients with COPD. Sleep. 2012;35(3):369-75. 
132. Valipour A, Lavie P, Lothaller H, Mikulic I, Burghuber OC. Sleep profile and symptoms of 
sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary 
disease. Sleep Med. 2011;12(4):367-72. 
133. Agusti A, Hedner J, Marin JM, Barbe F, Cazzola M, Rennard S. Night-time symptoms: a 
forgotten dimension of COPD. Eur Respir Rev. 2011;20(121):183-94. 
134. Rennard S, Decramer M, Calverley PMA, Pride NB, Soriano JB, Vermeire PA, et al. Impact 
of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD 
International Survey. European Respiratory Journal. 2002;20(4):799-805. 
135. Budhiraja R, Siddiqi TA, Quan SF. Sleep disorders in chronic obstructive pulmonary disease: 
etiology, impact, and management. J Clin Sleep Med. 2015;11(3):259-70. 
136. Budhiraja R, Roth T, Hudgel DW, Budhiraja P, Drake CL. Prevalence and polysomnographic 
correlates of insomnia comorbid with medical disorders. Sleep. 2011;34(7):859-67. 
137. Xiang YT, Wong TS, Tsoh J, Ungvari GS, Correll CU, Ko FW, et al. Insomnia in older adults 
with chronic obstructive pulmonary disease (COPD) in Hong Kong: a case-control study. 
COPD. 2014;11(3):319-24. 
138. Ohayon MM. Chronic Obstructive Pulmonary Disease and its association with sleep and 
mental disorders in the general population. J Psychiatr Res. 2014;54:79-84. 





140. Bednarek M, Plywaczewski R, Jonczak L, Zielinski J. There is no relationship between 
chronic obstructive pulmonary disease and obstructive sleep apnea syndrome: a population 
study. Respiration. 2005;72(2):142-9. 
141. Zamarron C, Garcia Paz V, Morete E, del Campo Matias F. Association of chronic 
obstructive pulmonary disease and obstructive sleep apnea consequences. Int J Chron 
Obstruct Pulmon Dis. 2008;3(4):671-82. 
142. McNicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnea: 
overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. Am J Respir 
Crit Care Med. 2009;180(8):692-700. 
143. Pronzato C. Chronic obstructive pulmonary disease and obstructive sleep apnea. Association, 
consequences and treatment. Monaldi Arch Chest Dis. 2010;73(4):155-61. 
144. Dzierzewski JM, Buman MP, Giacobbi PR, Jr., Roberts BL, Aiken-Morgan AT, Marsiske M, 
et al. Exercise and sleep in community-dwelling older adults: evidence for a reciprocal 
relationship. J Sleep Res. 2014;23(1):61-8. 
145. Holfeld B, Ruthig JC. A longitudinal examination of sleep quality and physical activity in 
older adults. J Appl Gerontol. 2014;33(7):791-807. 
146. Sachiko Inoue TY, Masumi Sugiyama, Toshiki Ohta, Kazuko Ishikawa-Takata, and Hiroyuki 
Doi. Does Habitual Physical Activity Prevent Insomnia? A Cross-Sectional and Longitudinal 
Study of Elderly Japanese Journal of Aging and Physical Activity. 2013;21:119-39. 
147. Baron KG, Reid KJ, Zee PC. Exercise to improve sleep in insomnia: exploration of the 
bidirectional effects. J Clin Sleep Med. 2013;9(8):819-24. 
148. Lambiase MJ. Temporal Relationships between Physical Activity and Sleep in Older Women. 
2013. 
149. Driver HS, Taylor SR. Exercise and sleep. Sleep Med Rev. 2000;4(4):387-402. 
150. King AC, Pruitt LA, Woo S, Castro CM, Ahn DK, Vitiello MV, et al. Effects of moderate-
intensity exercise on polysomnographic and subjective sleep quality in older adults with mild 




151. King AC, Oman RF, Brassington GS, Bliwise DL, Haskell WL. Moderate-intensity exercise 
and self-rated quality of sleep in older adults. A randomized controlled trial. JAMA. 
1997;277(1):32-7. 
152. Singh NA, Clements KM, Fiatarone MA. A randomized controlled trial of the effect of 
exercise on sleep. Sleep. 1997;20(2):95-101. 
153. Youngstedt SD, O'Connor PJ, Dishman RK. The effects of acute exercise on sleep: a 
quantitative synthesis. Sleep. 1997;20(3):203-14. 
154. Youngstedt SD, Perlis ML, O'Brien PM, Palmer CR, Smith MT, Orff HJ, et al. No association 
of sleep with total daily physical activity in normal sleepers. Physiology & Behavior. 
2003;78(3):395-401. 
155. Andrews NE, Strong J, Meredith PJ, D'Arrigo RG. Association between physical activity and 
sleep in adults with chronic pain: a momentary, within-person perspective. Phys Ther. 
2014;94(4):499-510. 
156. Pepin V, Boucetta S, Chan-Thim E, Parwanta Z, Gouin J-P, Dang-Vu TT. The Role of Sleep 
and Physical Activity on the Risk for Cardiovascular Disease. Current Cardiovascular Risk 
Reports. 2014;8(12). 
157. Chen R, Tian JW, Zhou LQ, Chen X, Yan HY, Zeng B, et al. The relationship between sleep 
quality and functional exercise capacity in COPD. Clin Respir J. 2014. 
158. Chennaoui M, Arnal PJ, Sauvet F, Leger D. Sleep and exercise: a reciprocal issue? Sleep Med 
Rev. 2015;20:59-72. 
159. Benefits and Risks Associated with Physical Activity, Benefits of Regular Physical Activity 
and/or Exercise. 2012. In: ACSM's Guidelines for Exercise Testing and Prescription 









161. Koskinen T, Kahonen M, Jula A, Mattsson N, Laitinen T, Keltikangas-Jarvinen L, et al. 
Metabolic syndrome and short-term heart rate variability in young adults. The cardiovascular 
risk in young Finns study. Diabet Med. 2009;26(4):354-61. 
162. Nunes DM, de Bruin VM, Louzada FM, Peixoto CA, Cavalcante AG, Castro-Silva C, et al. 
Actigraphic assessment of sleep in chronic obstructive pulmonary disease. Sleep Breath. 
2013;17(1):125-32. 
163. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Quantifying physical 
activity in daily life with questionnaires and motion sensors in COPD. Eur Respir J. 
2006;27(5):1040-55. 
164. Spruit MA, Gosselink R, Pitta F, Troosters T, Decramer M. Peripheral muscle strength 
training in patients with COPD. Chest. 2004;125(4):1589-90; author reply 90. 
165. Steele BG, Belza B, Cain K, Warms C, Coppersmith J, Howard J. Bodies in motion: 
monitoring daily activity and exercise with motion sensors in people with chronic pulmonary 
disease. J Rehabil Res Dev. 2003;40(5 Suppl 2):45-58. 
166. Chen JH, Waite L, Kurina LM, Thisted RA, McClintock M, Lauderdale DS. Insomnia 
symptoms and actigraph-estimated sleep characteristics in a nationally representative sample 
of older adults. J Gerontol A Biol Sci Med Sci. 2015;70(2):185-92. 
167. Kay DB, Buysse DJ, Germain A, Hall M, Monk TH. Subjective-objective sleep discrepancy 
among older adults: associations with insomnia diagnosis and insomnia treatment. J Sleep 
Res. 2015;24(1):32-9. 
168. Haba-Rubio J, Marques-Vidal P, Andries D, Tobback N, Preisig M, Vollenweider P, et al. 
Objective sleep structure and cardiovascular risk factors in the general population: the 
HypnoLaus Study. Sleep. 2015;38(3):391-400. 
169. Chan-Thim E, Dumont M, Moullec G, Rizk A, Wardini R, Trutschnigg B, et al. Clinical 
impact of time of day on acute exercise response in COPD. COPD. 2014;11(2):204-11. 
170. Littner M, Kushida CA, Anderson WM, Bailey D, Berry RB, Davila DG, et al. Practice 
parameters for the role of actigraphy in the study of sleep and circadian rhythms: an update 




171. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes 
and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, 
European Community for Steel and Coal. Official Statement of the European Respiratory 
Society. Eur Respir J Suppl. 1993;16:5-40. 
172. Galan AI, Palacios E, Ruiz F, Diez A, Arji M, Almar M, et al. Exercise, oxidative stress and 
risk of cardiovascular disease in the elderly. Protective role of antioxidant functional foods. 
Biofactors. 2006;27(1-4):167-83. 
173. Kushida CA, Chang A, Gadkary C, Guilleminault C, Carrillo O, Dement WC. Comparison of 
actigraphic, polysomnographic, and subjective assessment of sleep parameters in sleep-
disordered patients. Sleep Med. 2001;2(5):389-96. 
174. Tudor-Locke C, Camhi SM, Troiano RP. A Catalog of Rules, Variables, and Definitions 
Applied to Accelerometer Data in the National Health and Nutrition Examination Survey, 
2003–2006. Preventing Chronic Disease. 2012. 
175. Bromundt V, Koster M, Georgiev-Kill A, Opwis K, Wirz-Justice A, Stoppe G, et al. Sleep-
wake cycles and cognitive functioning in schizophrenia. Br J Psychiatry. 2011;198(4):269-76. 
176. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New Jersey: Lawrence 
Erlbaum Associates, Inc: Erlbaum Associates, Inc; 1988. 
177. Eliason G, Zakrisson AB, Piehl-Aulin K, Hurtig-Wennlof A. Physical activity patterns in 
patients in different stages of chronic obstructive pulmonary disease. COPD. 2011;8(5):369-
74. 
178. Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV. Meta-analysis of quantitative 
sleep parameters from childhood to old age in healthy individuals: developing normative 
sleep values across the human lifespan. Sleep. 2004;27(7):1255-73. 
179. Evering RM, Tonis TM, Vollenbroek-Hutten MM. Deviations in daily physical activity 
patterns in patients with the chronic fatigue syndrome: a case control study. J Psychosom Res. 
2011;71(3):129-35. 
180. Waterhouse J, Minors D, Atkinson G, Benton D. Chronobiology and meal times: internal and 




181. McSharry DG, Ryan S, Calverley P, Edwards JC, McNicholas WT. Sleep quality in chronic 
obstructive pulmonary disease. Respirology. 2012;17(7):1119-24. 
182. Hynninen MJ, Pallesen S, Hardie J, Eagan TM, Bjorvatn B, Bakke P, et al. Insomnia 
symptoms, objectively measured sleep, and disease severity in chronic obstructive pulmonary 
disease outpatients. Sleep Med. 2013;14(12):1328-33. 
183. Jung KI, Song CH, Ancoli-Israel S, Barrett-Connor E. Gender differences in nighttime sleep 
and daytime napping as predictors of mortality in older adults: the Rancho Bernardo study. 
Sleep Med. 2013;14(1):12-9. 
184. Lohne-Seiler H, Hansen BH, Kolle E, Anderssen SA. Accelerometer-determined physical 
activity and self-reported health in a population of older adults (65-85 years): a cross-sectional 
study. BMC Public Health. 2014;14:284. 
185. Buchman AS, Wilson RS, Yu L, James BD, Boyle PA, Bennett DA. Total daily activity 
















6.0 APPENDIX A:  Frequency distrebution of disease severity measured 
by FEV1 
 Frequency distribution data: FEV1















7.0 APPENDIX B: Manuscript - The Role of Sleep and Physical Activity on 
the Risk for Cardiovascular Disease 
Véronique Pepin1,2,3, Soufiane Boucetta1,3,4,5, Emilie Chan-Thim1,2,3,6, Zohra Parwanta1,2,3, Jean-
Philippe Gouin3,7, and Thien Thanh Dang-Vu1,3,4,5 
1Department of Exercise Science, Concordia University, 2Axe maladies chroniques, Centre de recherche de 
l’Hôpital Sacré-Coeur de Montréal, 3PERFORM Center, 4Centre de Recherche de l’Institut Universitaire de 
Gériatrie de Montréal, 5Center for Studies in Behavioral Neurobiology, Concordia University, 6Individualized 
Program, School of Graduate Studies, Concordia University, 7Department of Psychology, Concordia University, 
 
 
Keywords: Sleep, Physical activity, Sedentary behavior, Cardiovascular disease, Obesity, 
Metabolic syndrome, Diabetes, Cardiovascular events. 
 
Address for correspondence and reprint requests: 
 
Véronique Pepin (PhD) 
Associate professor, Dept. of Exercise Science, SP 165.29 
Concordia University,  
7141 Sherbrooke St. West 
Montréal, QC,  
CANADA, H4B 1R6 





Link to the article: http://link.springer.com/article/10.1007%2Fs12170-014-0413-6 
 






Sleep and physical activity are important health behaviors promoting cardiovascular health. 
Large bodies of literature have documented the direct effects of sleep and physical activity on 
risk factors for cardiovascular disease (CVD). This review aimed to highlight the interactive 
effect of sleep and physical activity on CVD risk. The extant literature suggests that sleep and 
physical activity are lifestyle behaviors that interact and act synergistically to influence CVD 
risk. Adopting healthy lifestyles encompassing both adequate sleep and regular physical activity 
is optimal to maintain cardiovascular health. 
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Maintaining a healthy lifestyle encompassing adequate sleep and regular physical activity 
(PA) promotes optimal health over the life course. Both poor sleep and physical inactivity 
increase risk for several physical and mental diseases [1-3].  
 Sleep is an important modulator of cardiovascular function in both health and disease 
conditions. Sleep duration has been linked with cardiovascular disease (CVD) risk. Indeed, 
several studies have suggested a U-shape association between sleep duration and mortality, with 
7 hours of sleep per day being associated with the lowest mortality, and shorter (6 or less) or 
longer (10 or more) sleeping time being associated with increased CVD mortality and morbidity 
[4-6]. Furthermore, the presence of certain sleep-related disturbances, such as obstructive sleep 
apnea, has been related to increased risk for the occurrence of cardiovascular events, such as 
myocardial infarction, coronary heart disease, heart failure, atherosclerosis, and ischemic stroke 
[7, 8], and to several CVD risk factors, such as obesity, hypertension, and diabetes [9, 10]. 
Insomnia is another risk factor for the development of CVD, such as coronary heart disease, and 
CVD risk factors such as hypertension, diabetes mellitus and metabolic dysregulation [11-13]. 
Periodic limb movements during sleep, another sleep-related disorder, has also been associated 
with greater risk for CVD [14]. Inadequate sleep resulting from behaviorally-induced shortened 
sleep or sleep disorders is thus a potential risk factor for CVD. 
 PA can be defined as any movement of the body generated by skeletal muscle contraction 
and resulting in increased energy expenditure [15]. Among healthy individuals, a dose-response 
relationship has been reported between PA and CVD risk, with highest levels of PA generally 
being linked with the greatest reduction in risk of CVD [16-18]. In individuals with stable 
coronary heart disease, an inverted J-shape association was recently documented, with patients 
reporting the lowest PA levels consistently having the highest hazards (for CVD events, CVD-
related and all-cause mortality), but also those reporting daily strenuous PA showing an 
increased mortality risk [19]. In 1995, a joint collaboration between the Center for Disease 
Control and the American College of Sports Medicine (ACSM) led to the first official 
recommendation to accumulate 30 minutes or more of moderate PA on most, preferably all, days 




recommendations to clarify that individuals wanting to improve fitness, prevent disease and 
reduce weight may need to exceed the minimum recommendations of at least 150 minutes of 
moderate activity per week [21]. More recently, sedentary behavior (SB), such as extended 
sitting time, has emerged as a potential risk factor independent from PA [22]. In other words, an 
individual that meets the PA recommendations but spends a large fraction of time in sedentary 
activities would still be at an increased risk of CVD [23]. Therefore, simply meeting the activity 
recommendations may not be enough to mitigate the deleterious effects of SB on cardiovascular 
health.   
The independent role of sleep and PA on CVD risk has thus been rather well 
documented, but how these two factors interact to affect CVD risk remains much less described. 
Therefore, the present review focuses on this potential interaction by summarizing recent 
literature investigating the interactive effect of sleep and PA on CVD risk, defined as the 
likelihood of having either a known CVD risk factor or a CVD event. In total, we reviewed 17 
recent studies (i.e., published within the last 15 years), which were conducted in heterogeneous 
populations, belonging to different geographical areas, ethnicities, ages, or genders. Studies were 
grouped into two categories: i) those related to cardiovascular risk profile (13 studies), and ii) 
those related to cardiovascular events (4 studies). Table 1 and Table 2 summarize the main 
methodological information pertaining to the reviewed studies from both categories. 
Sleep, Physical Activity, and Cardiovascular Risk Profile 
Sleep, Physical Activity, and Obesity 
Obesity is known to be a major risk factor for CVD and it is associated with increased 
mortality from CVD [24, 25]. Sleep, PA, and SB have each been shown to be independently 
associated with obesity in systematic reviews [26-28]. Only a few studies have examined sleep, 
PA, and SB together in relationship with obesity as the main outcome. In a cross-sectional study 
on Australian adults (N = 1 162), Di Milia et al. [29] looked at relationship between obesity 
defined as a body-mass index (BMI) ≥ 30 kg/m2, calculated from self-reported height and weight 
values and self-reported sleep duration. They found that obesity was significantly associated with 
short sleep duration (≤ 6 hours/day), and this association remained significant when adjusting for 




(i.e., extended sitting time) were also associated with obesity. However, being overweight (BMI 
= 25–29.99 kg/m2) was not found associated with sleep duration, PA or SB. All variables in this 
study were obtained through self-reports and thus not verified objectively, which constitutes the 
main limitation of these findings.   
Other studies have examined the effects of sleep, PA, and SB on objectively measured 
obesity markers. Vioque et al. [30] assessed the relationship between obesity and time spent in 
SB (i.e., watching TV) or sleeping, in a general adult Spanish population (N = 1 772, cross-
sectional). Sleep, leisure-time PA (LTPA), and SB were self-reported, while obesity was 
assessed by objectively measured BMI. They reported that obese people spent more time 
watching TV and less time sleeping. Watching TV ≥ 4 hours/day or sleeping ≤ 6 hours/day were 
both associated with higher odds ratio of obesity, after adjusting for LTPA and demographic 
variables. This effect followed a dose-response relationship for both variables: each additional 
hour of TV watching increased the odds ratio of obesity by 30 %, while each additional hour of 
sleep decreased the same odds ratio by 24 %. In this study, LTPA level was not associated with 
risk for obesity.  
In a large cross-sectional study, Forgelholm et al. [31] studied relationships between 
obesity, physical inactivity, sleep duration, and sleep-related disturbances (e.g., obstructive sleep 
apnea (OSA), insomnia-related symptoms concomitant with daytime tiredness) in 7 641 adults (> 
30 years old) from the general population in Finland. Screening questionnaires were used to 
assess sleep duration, probable sleep-related disturbances, and LTPA. The presence of abdominal 
obesity and overall obesity was objectively verified by the measurement of waist circumference 
(WC) and BMI respectively. Physical inactivity and probable OSA were independently 
associated with abdominal obesity (WC ≥ 102 cm in men, WC ≥ 88 cm in women). In addition, 
longer sleep duration (≥ 9 hours/day) was associated with lower likelihood of abdominal 
overweight (WC: 94-101 cm), but only in men. The study also included analyses of inverse 
models looking at the predictors of sleep duration and sleep disturbances. It was found that 
physical inactivity was associated with shorter sleep duration (≤ 6 hours/day) and that abdominal 
obesity decreased the likelihood for long sleep times and increased the likelihood for short sleep 
times, in men only. This relationship between abdominal obesity and sleep durations remained 




of both PA and sleep on obesity, and the bidirectionality between those factors and CVD risk, 
suggesting a vicious circle among physical inactivity, poor sleep, and abdominal obesity.  
While these previous studies were conducted on adult samples, some reports investigated 
the relationships between sleep, PA, SB, and obesity in adolescents. In a large cross-sectional 
study of 9 589 adolescents, Laurson et al. [32] investigated whether meeting healthy 
recommendations of sleep (≥ 8 hours/day), PA (≥ 1 hour/day) and SB (≤ 2 hours/day) influenced 
obesity as assessed by self-reported BMI. Youths that failed to meet healthy recommendations 
for any of the three behaviors were more likely to be obese. However, the effect of not meeting 
PA recommendations had a stronger influence on obesity than sleep or SB. They also showed 
that not meeting one recommendation increased odds of not meeting the two others, indicating 
the interdependent nature of these health behaviors. Furthermore, Garaulet et al. [33] assessed 
the association between short sleep duration and obesity in a large cross-sectional sample of 
European adolescents (N = 3 311). Sleep duration was estimated by a questionnaire, whereas PA 
and SB were assessed by both objective measure (i.e., accelerometry) and self-reported 
questionnaire. Objective morphometry measures (e.g., BMI, WC) were used to assess obesity. 
They showed that short sleep duration (< 8 hours/day) was associated with increased obesity 
markers. Interestingly, short sleep was also associated with increased SB (e.g., watching TV) and 
less adequate food habits, which suggests that the association between sleep and obesity was 
related to factors influencing both sides of the energy balance equation (i.e. energy consumption 
and expenditure).  
Few longitudinal studies have examined both sleep duration and PA in relation to obesity. 
In a cross-sectional analysis of 537 healthy adults, Chaput et al. [47] reported that both short 
sleep duration (6 hours or less per day) and the absence of high intensity PA were associated 
with BMI. In the 6-year follow-up of 283 of these individuals, short sleep duration was 
associated with a 1.65 kg greater weight gain over the follow-up period, while the absence of 
high intensity PA was associated with a more modest increase in weight (1.23 kg) over time. 
Among individuals who were not obese at baseline, short sleep duration increased the risk of 
becoming obese, independently of PA [34]. Similarly, in the Nurses’ Health Study, 68 183 
women aged 39-65 provided information on sleep duration in 1984 and self-recorded their 




weighed on average 2.47 kg more than those who slept 7 hours and 1.24 kg more than those 
sleeping 6 hours or less. Importantly, shorter sleep duration was also associated with a greater 
weight gain during the 16-year follow-up. Over the following 10 years, women who slept 5 
hours or less gained 0.73 kg and those sleeping 6 hours gained 0.26 kg more than did participants 
who slept 7 hours on average. Women who slept 5 hours of less were also 32 times more likely 
to experience a major weight gain of more than 15 kg during the follow-up than participants 
sleeping 7 hours. Importantly, the effect of sleep duration on weight gain was independent of PA 
[35].  
Sleep, Physical Activity, and Metabolic Profile 
Dyslipidemia (elevated low-density lipoprotein [LDL] cholesterol, reduced high-density 
lipoprotein [HDL] cholesterol, elevated total serum cholesterol, and/or elevated triglycerides), 
hypertension (elevated systolic and/or diastolic blood pressure [BP]), and a pre-diabetic state 
(impaired fasting glucose or impaired glucose tolerance) are well-recognized independent risk 
factors for CVD [36, 37]. Taken as a cluster which further includes abdominal obesity, these risk 
factors are sometimes referred to as the metabolic syndrome. There is no universally accepted 
definition for the metabolic syndrome, but criteria proposed by NCEP ATPIII Guidelines [38] 
and, more recently, by a World Health Organization (WHO) Expert Consultation [39] are 
commonly used. This clustering of metabolic factors is believed to be a stronger predictor of 
diabetes mellitus and CVD risk than the sum of individual factors [40], but its recognition as a 
distinct pathophysiology remains controversial [41]. Lifestyle behaviors influencing individual 
determinants of the metabolic syndrome are the same as for the syndrome itself and include 
sleep, PA/SB, smoking, and alcohol intake [42]. The following section presents findings from six 
studies, which have reported on the effects (independent and combined or interactive) of sleep 
duration and/or quality and PA and/or SB on metabolic risk factors, risk of metabolic syndrome, 
or diabetes incidence.  
First, in a cross-sectional analysis of data from the Woman on the Move through Activity 
and Nutrition (WOMAN) study [43], Casas et al. [44] examined the independent and combined 
associations between self-reported LTPA, sleep quality and duration (from the Pittsburgh Sleep 




overweight or obese women. Each behavior (LTPA, sleep quality, and sleep duration) was 
independently associated with at least one CVD risk factor in the expected direction after 
controlling for the other behaviors and known confounders (e.g., age, smoking etc.). In combined 
associations, women with higher LTPA (above median split) had better body composition and 
more favorable metabolic profiles compared to women with low LTPA (below median split), 
after controlling for sleep quality and duration. However, there were no association between 
sleep quality or duration and CVD risk factors in women of the same PA level. Nonetheless, 
several CVD risk factors (BMI, WC, trunk fat, total body fat, insulin, and HDL) went from most 
to least favorable across the following four categories: high PA/good sleep quality (PSQI score ≤ 
5), high PA/poor sleep quality (PSQI score > 5), low PA/good sleep quality, low PA/poor sleep 
quality, suggesting an interactive effect of PA and poor sleep quality on CVD risk.  
In another cross-sectional analysis of three cohorts (total N = 367) of adolescents, most 
with elevated blood pressure (72 %) and from a racial/ethnic minority (77 %), Countryman et al. 
[45] examined the interrelation between PA, aerobic fitness, and sleep with the metabolic 
syndrome and inflammation. Using structural modeling, direct associations of self-reported PA, 
measured aerobic fitness (peak oxygen consumption [VO2peak]), and self-reported sleep 
(duration, quality, and fatigue) with the metabolic syndrome and inflammation were tested. In 
addition, indirect associations, via fitness, of PA and sleep with the same outcomes were 
investigated. Their results suggested that reduced sleep duration, poor sleep quality and fatigue, 
and decreased PA were associated with decreased fitness, which was directly related to an 
increased risk of metabolic syndrome and inflammation in these at-risk youth. The concept that 
PA and sleep would be indirectly linked with metabolic profile through physical fitness is 
original and thought provoking. However, these findings, as well as those from Casas et al. [44], 
should be taken with consideration of the fact that they were derived from relatively small 
samples of specific at-risk populations (postmenopausal women and adolescents predominantly 
hypertensive and from a racial/ethnic minority). They were conducted using adequate 
measurement tools, but can nevertheless not be generalized to common adult populations.  
A handful of studies (three cross-sectional and one secondary analysis of a lifestyle 
intervention trial) have been conducted in representative adult samples from Portugal [42], 




association of 12-month recalls of PA, sleep duration, and other behaviors with the metabolic 
syndrome was examined in 2 164 Portuguese adults. After adjusting for confounders and other 
behaviors, greater total PA (males and females), work activities (females only), household 
activities (males only), and short (≤ 6 hours/day) sleep duration (females only) were associated 
with a lower risk for the metabolic syndrome. Longer sleeping hours (males and females) were 
independently associated with a higher risk of having the syndrome. The finding regarding a 
potential protective role of short sleep time contrasts with many prior reports, which have 
observed a U-shaped association between sleep duration and risk for obesity, metabolic 
syndrome, and type 2 diabetes [46] [49, 50]. However, this association was observed in female 
participants only. Furthermore, sleep duration and PA were based on a long (12-month) recall 
time, and sleep duration was assessed with a single interview question.  
In a secondary analysis of data from the Finnish Diabetes Prevention Study [51], a 
randomized controlled lifestyle intervention trial, Tuomilehto et al. [46] examined the 
association between sleep duration and type 2 diabetes in 522 overweight adults with impaired 
glucose tolerance. Participants in the larger trial were randomly allocated either to a group 
receiving an intensive individualized diet-PA counseling or to a control group. The median 
duration of the intervention and post-intervention periods were, respectively, four years and three 
years, for a total follow-up of seven years. Sleep duration was assessed at baseline and annually 
through 24-hour activity recall and grouped as ≤ 6.5 hours, 7-8.5 hours, 9-9.5 hours, and ≥ 10 
hours. Self-reported LTPA and other potential confounders were also measured at baseline and 
annually. Changes in sleeping hours during the follow-up period were minor, such that no 
significant shifting in sleep duration group occurred in either group. During the three-year post-
intervention follow up, about a third of participants (n = 182) developed diabetes. A trend for an 
increased risk for type 2 diabetes was seen in short sleepers (≤ 6.5 hours). Long sleep duration 
was significantly associated with increased diabetes risk in the control group, but not in the 
group receiving intensive individualized diet-PA counseling. This interaction between 
intervention group and sleep duration on diabetes incidence appeared to be independent of 
morphometric, metabolic, and inflammatory parameters, since these were similar across sleep 
duration groups at baseline and changed to a similar degree in both intervention arms. These 
findings suggest a potential protective role of intervention-induced increases in PA (or possibly 




and long sleeping durations. However, long sleepers in this trial were more likely to be on 
antihypertensive medication compared to other participants. This may have introduced a bias, 
since this type of medication has been associated with tiredness, fatigue, and sleep disorders 
[52].  
An important concept considered, but not accounted for, in these previous studies is the 
interdependent association between sleep, PA, and SB. In fact, the amount of time allocated to 
sleep, PA, and SB is inter-dependent: increasing time in one of these behaviors requires 
decreasing time in another, which may in turn affect CVD risk. In line with this concept, Buman 
et al. [47] used isotemporal substitution modeling to examine whether a decrease in one behavior 
in favor of another would be associated with objective changes in various CVD risk factors in a 
large cross-sectional analysis (N = 2 185) of data from the United States’ National Health and 
Nutrition Examination Survey (NHANES). Sleep duration was measured with a single interview 
question, while SB and PA (light and moderate/vigorous) were objectively measured with 
accelerometry. After holding all other time constant and adjusting for potential confounders, 
associations with a more favorable CVD risk profile were observed from reallocating time from 
SB to any other behavior, including sleep. However, moderate/vigorous PA appeared to be the 
most potent health-enhancing behavior, with 2-25 % improvements in waist circumference, lipid 
metabolism, and glucose metabolism seen from reallocating 30 minutes/day from SB (and, to a 
lesser extent, from sleep and light PA) to additional moderate/vigorous activity. In general, the 
observed benefits of reduced time in SB and more time in active behaviors were similar across 
sleep duration categories. In the limited cases where there was an interaction with sleep, less 
time in SB and more in active behaviors were typically protective or synergetic in very short 
sleepers (≤ 5 hours). Once again however, given the methodology used to assess sleep, no 
information was available on actual sleep duration (versus time in bed), sleep quality (objective 
or subjective in this case), or presence of a sleep disorder. 
Recently, in another cross-sectional analysis of NHANES data, Saleh and Janssen [48] 
investigated the associations between accelerometry-derived sleep duration (divided into 
quartiles) and SB (quartiles of sedentary time and tertiles of screen time) with the occurrence of 
the metabolic syndrome in 1 371 adults. Their main findings were that SB was very weakly and 




accelerometry-determined moderate/vigorous PA, sleep duration was not significantly associated 
to the metabolic syndrome or its components, while SB was, independent of sleep duration. 
Although sleep was objectively measured in this study, it was done so through a proxy estimate 
(longest non-wear period in a 24-hour cycle, with at least two valid measurement days). 
Accordingly, no details on the presence of a sleep disorder were available.    
 Together, these studies suggest that higher PA levels are consistently associated with 
improved CVD risk profiles even after adjusting for sleep. The impact of shorter or longer 
sleeping durations (compared to the average 7-8 hours/day) on CVD risk profile may vary 
according to levels of PA and/or SB. Increasing PA levels and/or reducing SB may have a 
protective effect in very short and very long sleepers, but this will have to be confirmed. Most 
studies conducted to date have been cross-sectional and have used subjective measures of sleep 
and PA. Future research with longitudinal or experimental designs and objective assessments of 
sleep (duration and quality) and PA is needed. In addition, the impact of experimentally 
reallocating time from SB to sleep and/or PA should be investigated. 
Sleep, Physical Activity, and Cardiovascular Events  
Several population-based epidemiological studies have evaluated the impact of subjective 
measures of PA and sleep on the incidence of fatal [53-55] and non-fatal [53, 55] cardiovascular 
(CVD) events. In a longitudinal study of 6 672 men and 7 769 women from the Netherlands, 
sufficient physical activity, defined as at least 3.5 hours of cycling or sports per week, and 
sufficient sleep, defined as a sleep duration of at least 7 hours, were both independently 
associated with lower incidence of fatal and non-fatal CVD events over the follow-up period 
lasting an average of 12 years [53]. Furthermore, adoption of a greater number of healthy 
lifestyle behaviors, including PA, sleep, smoking status, alcohol consumption, and a 
Mediterranean diet, was associated with greater decreases in risk for CVD events, highlighting 
the cumulative impact of these different lifestyle behaviors. 
Similar findings were observed in a sample of 44 056 participants from the Singapore 
Chinese Health Study [55]. Cardiovascular mortality was higher among individuals with sleep 
durations of less than 6 hours or more than 9 hours per night and among individuals with less 




protective lifestyle factors, including sleep, PA, smoking, alcohol intake, dietary, and BMI, was 
associated with a linear decrease in coronary heart disease, cerebrovascular disease and overall 
cardiovascular mortality. This effect was observed for both healthy individuals and individuals 
with a history of CVD or diabetes mellitus at enrollment.  
In a 16.5-year longitudinal of 44 301 Japanese individuals, the adoption of multiple 
healthy lifestyle behavior was associated with lower cardiovascular mortality [56]. In this study, 
walking ≥ 1 hour/day, participating in sport ≥ 5hour/week, and sleeping 5.5-7.4 hour/night were 
considered protective. When considering individuals with the lowest (0-2) healthy lifestyle 
scores compared to those with the highest (7-8) scores, mortality rate from stroke, coronary heart 
disease, and other CVD decreased to 1/3rd for men and 1/4th for women. 
In a 15-year follow up of 70 973 Swedish participants, Bellavia et al. [54] specifically 
investigated the relationship between sleep duration and CVD-related mortality across categories 
of PA. Results indicated that cardiovascular mortality was higher among participants with a sleep 
duration of less than 6 hours or more than 8 hours per night, than for participants with a sleep 
duration of 7 hours. However, this effect was modulated by PA. Although short sleep duration 
was associated with higher mortality at all PA levels, the effect was more pronounced among 
individuals in the lower PA tertile. Furthermore, long sleep duration (> 8 hours) was associated 
with greater mortality only for individuals in the lower PA tertile. This is in line with the 
suggestions that low levels of PA influence the association between long sleep duration and 
mortality rate [57].     
Collectively, results from these epidemiological studies indicate that adopting a greater 
number of healthy lifestyle behaviors decrease CVD risk [55-58], that sufficient sleep makes a 
unique contribution to this reduction [55], and that sleep and physical activity interact to predict 
CVD risk, such as the impact of short and long sleep duration on CVD mortality is greater 
among individuals with lower PA level [56].  
Bidirectional relationship between PA and Sleep  
 In addition to the interactive effect of PA and sleep on CVD risks, there seems to be a 




greater involvement in PA is associated with overall better sleep quality [58]. Randomized 
exercise intervention studies corroborate that involvement in regular PA, particularly aerobic 
exercise, is associated with an improvement in both subjective and objective sleep quality [59, 
60], although this effect appears to be more pronounced among individuals with poor sleep [61]. 
A few recent studies have specifically examined the reciprocal relationship between PA and 
sleep. In a 2-year longitudinal study with healthy older adults, cross-lagged analysis indicated 
that sleep quality at baseline predicted PA at the 2-year follow-up [62], while baseline PA did 
not predict subsequent sleep quality. Furthermore, in a daily diary study in women with 
insomnia, poor sleep on a given night was associated with shorter exercise duration the following 
day, but exercise duration on a given day did not predict sleep quality on the corresponding night 
[63]. A similar pattern of results was observed among older adults without sleep complaints. 
Participants reported more PA following nights when their sleep quality was rated as above their 
personal mean sleep quality level and they reported better sleep quality following days when 
their PA levels was above their personal mean PA level [64] Taken together, these results 
suggest that involvement in regular physical activity is associated with an overall improvement 
in sleep quality. However, poor sleep on a given night can impact involvement in PA the 
following day. Individuals with sleep complaints may be particularly sensitive to the effect of 
poor sleep on next-day involvement in PA. These data highlights the importance of considering 
poor sleep as an obstacle to the maintenance of regular PA.    
Limitations and future directions 
The majority of studies published to date have used subjective measurements, such as 
self-administered questionnaires, to evaluate sleep and PA. Moreover, the specific subjective 
tools used and the grouping values for each behavior have differed from one study to the other. 
This could explain some of variability in the findings. Further research with more objective 
measurements, especially for sleep, is needed to overcome this limitation. Likewise, most studies 
have been cross-sectional and observational in nature and other confounding factors, such as age, 
gender, and socio-economic status, have not always been taken in consideration. Therefore, more 
longitudinal follow up studies are needed to clarify the independent, combined, and interactive 





In summary, adequate sleep and higher PA are both necessary to maintain a healthy 
lifestyle and prevent risk to develop CVD. Furthermore, sleep and PA are lifestyle behaviors that 
can interact to influence CVD risk. Overall, maintaining optimal sleep duration and sleep quality, 
reducing sedentary time and increasing PA, especially moderate to vigorous PA, seems to be the 
best method to manage risk of metabolic syndrome and subsequent CVD. In addition, fatal or 
non-fatal cardiovascular events can be prevented or postponed by obtaining adequate average 
sleep duration (7-8 hours/day) and greater levels of PA in combination with other protective 
lifestyle factors, such as well balanced dietary pattern, light-moderate alcohol consumption, non-
smoking, and maintenance of a healthy body weight. More intervention studies simultaneously 
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Table 1. Methodological Overview of Studies on the Interactive Effect of Sleep and PA on Cardiovascular Risk Profile 
Reference Design Study Population Independent Variables Dependent Variables N (M:F) Descriptives Sleep Activity 
Di Milia et 
al., 2013 [29] Cross-sectional 
N=1 162 
(450:622) 
Random sample of Australian 
adults 
Age=45.2 ± 11.2 yrs 
 
Sleep duration (self-report 
questionnaire) 




BMI (from self-reported 
values) 
Vioque et al., 
2000 [30] Cross-sectional 
N=1 772 
(814:958) 
Random sample of Spanish 
adults 




(self-reported questionnaire)  BMI (objectively measured) 
Forgelholm 




N = 7 641  
(3 377:4 264) 






LTPA (questionnaire) WC and BMI (objectively measured) 
Laurson et 
al., 2014 [32] Cross-sectional 
N = 9 589 
(4 715:4 874) 
U.S. high-school students 
(grades 9-12) 




BMI (from self-reported 
values) 
Garaulet et 
al, 2011 [33] 
Cross-sectional 
 
N = 3 311 
 (1 563:1 748) 
European adolescents                       
Age=12.5–17.5 yrs 
Sleep duration (interview 
question) 
PA (accelerometry and  
IPAQ-A) 
Morphometry (BMI, WC, hip 
circumference, body fat, fat 
mass index) 




N = 283 
(121:162) 
Sample of French Canadian 
adults from white two-parent 
families, more than half of 
which included at least one 
parent or offspring with BMI ≥ 
32 kg/m2 
Age=18-64 yrs (baseline) 
Sleep duration (self-report 
questionnaire) 
PA (self-reported 3-day 
activity diary) 
Weight and BMI (objectively 
measured) 





N = 68 183 
(0:68 183) 
Sample of female, married 
registered nurses, free of 
comorbid disease 
Age=39-65 yrs (baseline) 




Weight and BMI (from self-
reported values) 
Casas et al., 
2012 [44] Cross-sectional 
N = 393 
 (0:393) 
Postmenopausal 
overweight/obese women  
 Age=62±3 yrs 
Sleep quality 




Morphometry (BMI, WC), 
body composition (DXA), 
BP, blood profile (total 
cholesterol, triglycerides, 
HDL-C, insulin, glucose) 
Countryman et al., 
2013 [45] Cross-sectional 




Sleep duration (7-day 
interviewer-administered 
AR), sleep quality and 
fatigue (items 16-17 from 
the CDI) 
PA (7-day interviewer-
administered AR), aerobic 
fitness (measured VO2peak) 
Occurrence of metabolic 
syndrome (defined based on 












 (832:1 332) 
Random sample of Portuguese adults 
Age =18-92 yrs 
Sleep duration (single 
interview question, 12-
month recall) 
Total PA, work activities, 
household activities, LTPA 
(all in MET/hour), regular 
exercise (yes/no) (interview 
questionnaire, 12-month 
recall) 
Occurrence of metabolic 
syndrome (defined according 
to NCEP-ATPIII [38]) 
Tuomilehto 
et al., 2009 
[46] 
Secondary analysis 




Overweight Finnish adults with 
impaired glucose tolerance 
Age= 45-64 yrs 




Incidence of diabetes 
(defined as per WHO 1985 
criteria [66]) per 100 person-
years 
Buman et al., 
2013 [47] Cross-sectional 
Full sample: 
N=2 185 




Random sample of the U.S. 
civilian non-institutionalized 
population 
 Age ≥ 20 yrs 
Sleep duration (single 
interview question with 5 
levels: ≤ 5 hours, 6 hours, 
7 hours, 8 hours, or ≥ 9 
hours) 
SB (<100 counts/min), LIPA 
(100-1951 counts/min), 
MVPA (≥ 1952 counts/min) 
(7-day accelerometry) 
Morphometry (WC), BP, 
blood profile (nonfasting 






Cross-sectional N=1 371 (770:601) 
Random sample of the U.S. 
civilian non-institutionalized 
population 
 Age ≥ 20 yrs 
Sleep duration 
(accelerometry-derived 
proxy estimate from 
longest non-wear period in 
24-hour cycle on ≥ 2 valid 
days) 
SB, divided into screen time 
(2 interview questions) and 
sedentary time (time spent 
below 100 counts/min with 
7-day accelerometry) 
Occurrence of metabolic 
syndrome (defined according 
to criteria from a WHO 
Expert Consultation [39]) 
AR: Activity Recall, BMI: Body Mass Index, BP: Blood Pressure, CDI: Children’s Depression Inventory, CRP: C-Reactive Protein, DXA: Dual-Energy X-Ray 
Absorptiometry, F: Females, HDL-C: High-Density Lipoprotein Cholesterol, IL-6: Interleukin-6, IPAQ: International Physical Activity Questionnaire, IPAQ-A: 
International Physical Activity Questionnaire for Adolescents, LIPA: Light-Intensity Physical Activity, LTPA: Leisure-Time Physical Activity, M: Males, MVPA: 
Moderate-to-Vigorous Physical Activity, MAQ: Modifiable Activity Questionnaire, MET: Metabolic Equivalent of Task, NCEP-ATPIII: National Third Report of the 
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 
III), PA: Physical Activity, PSQI: Pittsburgh Sleep Quality Index, SB: Sedentary Behavior, SRD: Sleep-Related Disturbances, VO2peak: Peak Oxygen Consumption, 





Table 2. Methodological Overview of Studies on the Interactive Effect of Sleep and PA on Cardiovascular Events 
Reference Design Study Population Independent Variables Dependent Variables N (M:F) Descriptives Sleep Activity 
Hoevenaar-Blom 
et al., 2013 [53] 
Retrospective 
analysis, Between 
1994-1997, End of 
follow-up 2008 
N=14 639 
(6 672:7 967) 
Europeans (Dutch) 




<7 vs ≥7hrs/night 
Cycling and sport 
(self-administered 
questionnaire) 
_<3.5 vs. ≥3.5 
hrs/wk cycling and 
sports 
CV events (nonfatal or 
fatal MI, stroke) 








Age=45-74 yrs, (44 056 without a history 
of DM, CVD, or cancer and 6 410 with 








<2 vs. ≥2 hrs/wk of 
moderate or any 
strenuous activity 
CV events (mortality 
from CVD, CHD, 
stroke) 




1988-1990, End of 
follow-up 2006 
N=43 010  
(18 747:24 263) 
Japanese  
Age =40-79 yrs 





<5.5. and ≥ 7.5 
hrs/night 
Walking <.5h/day or 
exercise < 5h/week vs ≥ .5hr/days or 





CV events (mortality 
from CVD, CHD, and 
stroke) 






N=70 973  
(37 846:33 127) 
Swedish 





Activity levels during 
different activities 
1st tertile = <39.3 
MET hrs/day 
2nd tertile = 39.3–44.2 
MET hours/day 
3rd tertile = >44.2 
MET hours/day 
CV events (mortality 
form CVD and stroke) 
CHD: Coronary Heart Disease, CV: Cardiovascular, CVD: Cardiovascular Disease, DM: Diabetes Mellitus, F: Females, M: Males, MVPA: Moderate-to-Vigorous 
Physical Activity, MET: Metabolic Equivalent of Task, MI: Myocardial Infarction. 
 
 
